|Steven Larson||Memorial Sloan Kettering Cancer Center|
Head, Larson Lab
Steven M. Larson, MD., FACNM, FACR is currently the Donna and Benjamin M. Rosen Chair; Attending, Molecular Imaging and Therapy Service, Department of Radiology; Co-Leader, Imaging and Radiation Sciences, Member, Laboratory Head, Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center. Dr. Larson’s primary expertise is in radiolabeled drug development and radiopharmacology of diagnostic imaging and therapy in oncology using small molecules and monoclonal antibodies. Dual-boarded in nuclear medicine and internal medicine, his clinical skills center on oncology, cancer immunology, and clinical thyroid cancer. Dr. Larson has extensive experience as an advisor to public and private institutions, having served, among other appointments, as a member of what is now the MEDI grant review committee of NIH, the DOE Office of Science Advisory Committee, and the American Board of Nuclear Medicine, and as Chair of the Radiopharmaceutical Advisory Committee of the USFDA, Co-Chair of the National Research Council of the NAS Committee on Molybdenum-99 production with non-enriched Uranium 235, Chair of the Molecular Imaging Committee of RSNA, and Co-Chair of the Clinical Imaging Steering Committee of the NCI, and Chair of the NIH Clinical “Impact” Study Section, as well as a member of the Academy of Medicine. Dr. Larson has received numerous awards for excellence in nuclear medicine, including the Hevesy Award, Cassen Prize, Wiley Prize (US FDA), and the Saul Hertz Award of the Society of Nuclear Medicine USA. He is a member of the National Academy of Medicine of the National Academies of Science, USA.
|Brenda Laster||Ben Gurion University of the Negev|
Associate Professor Nuclear Engineering & Director, Jerry J Cohen Radiobiology Lab
Professor Laster received her B.S. in biology from Stern College for Women, New York, NY and her graduate studies were carried out at Memorial/Sloan Kettering, New York NY, where her major was Diagnostic Cytology. Her Ph.D. studies in experimental pathology and radiation biology were carried out at the State University of New York at Stony Brook, Stony Brook, NY and the Union Institute, Cincinnati, Ohio. Her thesis was on “Binary Systems for the Improvement of Cancer Radiotherapy” and her thesis advisor was Victor P. Bond, M.D., Ph.D. Before joining the faculty of Ben Gurion University, Professor Laster was a scientist in the Medical Department of Brookhaven National Laboratory in Upton, N.Y. and an Assistant Professor in the Department of Radiation Oncology in the School of Medicine at the State University of New York at Stony Brook. She served as a visiting professor in the Department of Radiation Physics at the University of Lund, Lund, Sweden, and in the Social Dimensions of Science, Project WISE, at the State University of New York at Stony Brook, Stony Brook, N.Y.
|Fides Lay, PhD||Amgen Inc|
Scientist, Cell Line Developmentelopment & Genetic Characterization
Fides Lay received her Ph.D. in Genetics, Molecular and Cellular Biology from the Keck School of Medicine at University of Southern California in 2014 after completing a thesis on the epigenetic regulation of tumorigenesis. She went on to complete a postdoctoral fellowship at the University of California, Los Angeles where she developed and implemented high-throughput sequencing-based assays as well as genetic editing tools to study the mechanism of normal and malignant blood development. Fides joined Amgen’s Cell Line Development and Genetic Characterization team in 2018. She is interested in developing better methods to generate and characterize cell lines for multiple biotherapeutics modalities.
|Greg Lazar||Genentech Inc|
Director & Senior Scientist, Antibody Engineering
Greg Lazar received his BS in Molecular & Cell Biology and Chemistry from Penn State, his PhD in Molecular & Cell Biology from the University of California at Berkeley, and did postdoctoral research at the University of Cambridge, UK. Previously he led research groups at Eli Lilly and Xencor. Currently he is Director and Senior Scientist in Antibody Engineering at Genentech where he oversees antibody technology platforms, high-throughput protein production, and infrastructure for automation, software, and informatics. His research group is focused on the development of novel antibody technologies to enable next generation therapeutics to treat unmet medical needs in oncology and neuroscience.
|Robert Lechleider||Seattle Genetics Inc|
Senior Vice President, Clinical Research
Robert J. Lechleider, M.D. is Senior Vice President, Clinical Development at Seattle Genetics where he is responsible for directing development of the early and late stage portfolios. Previously, Dr. Lechleider held key roles at several biopharmaceutical companies, including MacroGenics and MedImmune. Before joining the biotechnology industry, he served as Assistant Professor of Pharmacology at Uniformed Services University of the Health Sciences, and Associate Professor of Cell Biology at Georgetown University Medical School. Dr. Lechleider received his A.B. cum laude from Princeton University and his M.D. from the University of Illinois College of Medicine at Chicago. He received clinical training in internal medicine at Beth Israel Hospital in Boston and in medical oncology at the National Cancer Institute in Bethesda. He was also a Howard Hughes Medical Institute Scholar and a Damon Runyon-Walter Winchell postdoctoral fellow.
|Jiwon John Lee||Dartmouth College|
Assistant Professor, Engineering
Jiwon Lee is Ralph and Marjorie Crump Assistant Professor in Thayer School of Engineering at Dartmouth College. He received his BA in Molecular and Cell Biology from the University of California, Berkeley, and his PhD degree in Chemical Engineering at the University of Texas at Austin. His research group is interested in developing cutting-edge technologies for immune profiling to understand how antibody repertoires impact health and disease in the context of infectious disease, autoimmunity, and cancer, then applying this knowledge as a guide for engineering next-generation prophylactics and therapeutics.
|Elissa Leonard||Johns Hopkins University|
PostDoctoral Research Fellow, Biomedical Engineering
Dr. Elissa Leonard attended Harvery Mudd College, where she received her B.S. in Biomolecular Systems and Design, and developed novel bioreactor designs for corneal tissue engineering with Dr. Elizabeth Orwin. She earned her Ph.D. at the University of Texas at Austin, where her research focus shifted to engineering therapeutically relevant autoimmune T cell receptors under the supervision of Dr. Jennifer Maynard. Currently, Dr. Leonard is a Postdoctoral Fellow at Johns Hopkins University, where she has continued research in protein and immune engineering with Dr. Jamie Spangler. Currently, her work focuses on engineering antibody-cytokine fusion proteins that can shift the immune balance and promote anti-tumor or pathogen-clearing immune activity. She is also revisiting her regenerative engineering roots by engineering of growth hormones for applications in osteogenesis.
|Nancy Levin||Triphase Accelerator Corp|
Nancy Levin joined Triphase in 2015 with more than 20 years’ experience in the biotechnology industry, and technical expertise in clinical and translational pharmacology and nonclinical development. Nancy was Vice President of Therapeutics Product Design Group at Intrexon Corporation (2013-2014), where she oversaw the conception and development of novel therapeutic partnering opportunities enabled by Intrexon’s proprietary cell- and DNA-based technologies. Prior to this, Nancy held positions of increasing responsibility at Pfizer (CovX Research, 2005-2013), X-Ceptor Therapeutics (2003-2004), MitoKor (2001-2003), and Trega Biosciences (1999-2001). Nancy’s biotechnology experience began at Genentech (1993-1996), followed by Amgen (1996-1999), where she led multiple discovery and target validation projects. Her breadth of therapeutic area expertise includes oncology, metabolic and cardiovascular diseases, dermatology, inflammation, endocrinology, and rare/ultra-rare genetic diseases. She has led programs from discovery into clinical proof-of-concept employing multiple therapeutic modalities including small molecules, antibody-drug and -peptide conjugates, peptides, proteins, and antibodies. Nancy’s development experience includes 19 IND/CTA filings, and 11 Phase 1 and 6 Phase 2 clinical proof-of-concept studies, responsible for clinical PK and biomarker study design and execution, PK modeling, clinical efficacy and safety data analysis and presentation, clinical protocol design and development, IND and Orphan Drug applications and annual reports, and complete IND-enabled submission packages for small and large molecules. She earned a Ph.D. in Endocrinology at the University of California San Francisco, followed by post-doctoral training in the Fishberg Research Center for Neurobiology at The Mount Sinai School of Medicine in New York, NY.
|Nathan Lewis, PhD||University of California San Diego|
Associate Professor, Pediatrics
Dr. Lewis is an Assistant Professor of Pediatrics and Bioengineering at the University of California, San Diego. He received his BS in biochemistry at Brigham Young University, and his PhD at UC San Diego, where he focused on proteomics and developing novel approaches for analyzing biological big data using genome-scale systems biology modeling techniques. Dr. Lewis completed his postdoctoral training at the Wyss Institute at Harvard Medical School, where he worked on genome editing and the use of systems biology for the interpretation of genetic screens. Dr. Lewis' lab integrates all of his previous work by focusing heavily on the use of systems biology and genome editing techniques to map out and engineer the cell pathways controlling mammalian cell growth, protein synthesis, and protein glycosylation.
|Yang Li||Surrozen Inc|
Vice President Biology
Dr. Yang Li is Vice President of Biology at Surrozen. He holds a Ph.D. degree in Cell Biology from Stanford University and has over 20 years experience in biopharmaceutical industry with successes in advancing drug molecules from concept to clinic. Dr. Li has expertise in several classes of targets from enzymes, transcription factors, to membrane receptors and secreted hormones. He has 77 peer-reviewed publications and over 22 published patent applications.
|Jennifer Lin-Jones||Eurofins DiscoverX|
Senior Group Leader, Assay Development, Research & Development
Cell biologist at Eurofins DiscoverX overseeing development of cell-based assays for drug discovery and pharmacology, across multiple therapeutic areas and target classes.
|Thomas Little, PhD||Bioassay Sciences, Thomas A Little Consulting|
President and CEO
Dr. Little is President of BioAssay Sciences (BAS) a globally recognized bioassay consulting company for biologicals and vaccines. BAS specializes in the design, calculation and control of potency and relative potency for bioassays. BAS specializes in In-Vivo and In-Vitro bioassays. BAS works with international companies and health authorities globally to achieve product development goals aligned to ICH and USP guidance. BAS is a strategic partner of SAS/JMP and a division of Thomas A. Little Consulting. Dr. Little has developed specific content courses in statistical methods and data analysis, Bioassay Design and Validation, Quality Risk Management, design of experiments, Robust Optimization, Design Space and Tolerance Design, Assay Development and Method Validation, statistical process control, mixture design of experiments, Stability Analysis and Nonlinear Modeling. These courses are used by a variety of fortune 100+ companies to train their chemists, engineers and scientists.
|Liming Liu||Curon Biopharmaceuticals Shanghai Co Ltd|
Senior Vice President & Head, Product Development
Dr Liu currently serves as Senior Vice President of Curon Biopharmaceuticals Co. Ltd. He obtained his Ph.D. in immunology at University of Oxford followed by several years’ postdoc work at Harvard University before working in biotech industry in early 2000. Dr Liu has extensive experience in the discovery and development of mAbs and Fc-fusion proteins. He was the head of Immunology group of Syntonix Pharmaceuticals (acquired by Biogen, then Sanofi), working on mAb and Fc-fusion molecule discovery programs. Prior to joining Curon Biopharmaceuticals, He was a Senior Principal Scientist of Merck Research Laboratories for 12 years at the department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM), responsible for more than a dozen of Merck Biologics programs including monoclonal antibodies and Fc-fusion proteins from discovery to development and regulatory filings.
Principal Scientist, Biologics R&D
Lin is currently a Principal Scientist in Sanofi. She is working on developing analytical characterization methods to understand structure-function relationship and critical attributes of biological drug products, including mAb, bispecific antibodies, fusion proteins, recombinant lysosomal enzymes, and gene therapy products. Lin has strong expertise in LC/MS method development, protein structure characterization, degradation pathway and comparability studies. Before joining Sanofi/Genzyme, Lin worked as a senior scientist at Wyeth, Ariad and Abbot Laboratories. Lin earned her Ph.D. in Chemistry from University of Michigan Ann Arbor.
No bio available
|Tina Liu, MBA||Ally Therapeutics|
Co-Founder and CEO
Tina serves as co-founder/CEO of Ally Therapeutics, an innovative company dedicated to solving the immune response barriers for gene therapy. She spun the company out of the Wyss Institute at Harvard, where she had supported the foundational research as an Entrepreneur-in-Residence. Prior, Tina was a private equity investor at TPG Capital, where she evaluated potential investments $1Bn+ in size across commercial pharma and other sectors of the healthcare industry. Before that, Tina was an investment banker at Morgan Stanley, where she advised healthcare companies on key transactions including mergers and acquisitions, equity and debt financings, and other strategic alternatives. Tina received her MBA with Distinction from Harvard Business School and her BA, magna cum laude, from Harvard College.
|Rihe Liu, PhD||University of North Carolina, Chapel Hill|
Associate Professor, Chemical Biology and Medicinal Chemistry, Eschelman School of Pharmacy
Professor Rihe Liu’s laboratory at the Eshelman School of Pharmacy and Carolina Centre for Genome Sciences at UNC Chapel Hill focuses on the directed molecular evolution of novel multifunctional target-binding molecules from natural and unnatural biopolymer libraries with high diversity and use the resulting affinity ligands in various modalities, including the protein, the mRNA as well as the engineered immune cells, to specifically target cancer cells or modulate the immunosuppressive tumor microenvironment for combination immunotherapy.
|Brian Long||BioMarin Pharmaceutical Inc|
Associate Director & Senior Scientist II, Translational Sciences & Immunogenicity Assessment
Brian Long received his Ph.D. in Microbiology and Immunology from The University of North Carolina, Chapel Hill in 2004 and pursued post-doctoral training at The Gladstone Institutes and the University of California, San Francisco where he investigated the role of innate immunity in HIV disease pathogenesis. Following his post-doctoral training, he continued as a Research Scientist in the Division of Experimental Medicine at UCSF where he worked on the development and standardization of humanized mouse models for the evaluation of HIV immunology, therapeutics and drug discovery. Brian joined BioMarin in June of 2014 and is currently an Associate Director in Translational Sciences and Immunogenicity Assessment where he provides immunologic expertise to drug programs across developmental stages and develops immunogenicity and safety strategies for novel biologic therapeutics. Brian has over 20 years of experience in immunology and infectious disease, autoimmunity, cell signaling, cancer biology and drug development.
|James Love, PhD||Novo Nordisk AS|
Director, Applied Automation
Dr. James Love is Director of Applied Automation in the division of Global Research Technologies, Novo Nordisk A/S. James was educated at Oxford and Cambridge Universities, where he trained as a structural biologist. He worked in academia and biotech in the USA for 15 years, where his work has been focused on the high throughput and automated production of proteins for biologics discovery and optimization; he also investigates other applications of software and hardware automation, including robotics, to drug discovery.
|Lisa Lundberg||Spark Therapeutics|
Bioassay and Cell Culture Lead
Lisa Lundberg currently leads the Bioassay team in the Analytical Sciences group at Spark Therapeutics. She is primarily responsible for the development and validation of potency and infectivity assays, supporting Spark Therapeutics pipeline. She has over 25 years of experience in pharma and biotech, government and contract testing industries, developing potency, PK, immunogenicity and NAb assays for protein drug products, vaccines and gene therapies. She holds a BSc from Case Western Reserve University.
|Robert Lutz||Iksuda Therapeutics|
Bob Lutz serves as Chief Scientific Officer of Iksuda Therapeutics and has extensive experience in the development of antibody-based therapeutics. With more than 25 years’ experience, Bob was previously Vice President of Translational Research and Development at ImmunoGen, where he was responsible for all early-stage ADC development programs and directly the clinical pharmacology, biomarkers, pharmacology and toxicology departments. While at ImmunoGen, Bob was responsible for bringing multiple ADC candidates through development and was ImmunoGen’s research lead for the FDA-approved trastuzumab emtansine.
|Mark Ma||Alexion Pharmaceuticals Inc|
Executive Director, Bioanalytical Development
Mark Ma is Executive Director of Bioanalytical Development at Alexion Pharmaceuticals. His group provides bioanalytical and Biomarker support to Alexion projects, including large molecule, small molecule, and RNAs. Before Alexion, Mark was a director of large molecule bioanalytical sciences at Amgen. Mark has been active in American Association of Pharmaceutical Scientists (AAPS) and service as chair of PK assay group within Ligand Binding Assay committee. Mark had held several academic research positions with UCLA and MMRI. His professional career outside of industry includes being a reviewer for several scientific journals and giving lectures to local colleges/universities.
|Jad Maamary||Merck & Co Inc|
Assistant Principal Scientist, Predictive & Clinical Immunogenicity
Jad Maamary is an Associate Principal Scientist at Merck and Co., Inc. Dr Maamary is responsible for developing and implementing novel in silico and ex vivo platforms to assess the immunogenicity of biologics, vaccines and tumor-associated neoepitopes. His current work investigates the interplay between immunomodulation and immune receptor cross-reactivity leading to breaking of immune tolerance. Prior to Joining Merck, Dr Maamary completed a postdoctoral fellowship at the Rockefeller University under the mentorship of Jeffrey Ravetch. He discovered a novel IgG-Fc receptor on B cells which led to the development of an innovative vaccination regimen that took advantage of pathways involved in autoimmune diseases to enhance the efficiency immunization. Dr Maamary obtained his PhD in Molecular Virology and Immunology at the Mount Sinai School of Medicine. Under the mentorship of Dr Peter Palese he investigated viral immune evasion and helped conceptualize and develop universal vaccines for Influenza.
|Daniel MacLeod||Precision BioSciences|
Director, Cell Therapy Discovery
Dr. MacLeod is currently leading the Cell Therapy Discovery Team at Precision BioSciences. His team is responsible for cell therapy discovery research and preclinical development efforts using Precision’s ARCUS gene-editing technology to engineer human T cells for cancer therapy. Dr. MacLeod was the lead author on a manuscript describing Precision’s process for engineering off-the-shelf allogeneic CAR T cells published in Molecular Therapy and is co-inventor on several granted and pending patents related to Precision’s off-the-shelf CAR T technology. Precision’s first cell therapy product, PBCAR0191, a gene-edited allogeneic CAR T cell candidate targeting CD19, developed in collaboration with Servier, is currently in clinical trials. Prior to joining Precision, Dr. MacLeod was an Investigator at GlaxoSmithKline working on immunomodulatory drug discovery programs. He performed his postdoctoral work at the International AIDS Vaccine Initiative Neutralizing Antibody Center at the Scripps Research Institute, and at the University of California, San Diego. Dr. MacLeod received a B.A. from Northwestern University with a double major in Biochemistry and Psychology, and a Ph.D. in Molecular Pathology and Biomedical Sciences from the University of California, San Diego.
|Donald Mager||SUNY Buffalo|
Professor & Vice Chair, Pharmaceutical Sciences
Don is a founder and serves as President and Chief Executive Officer (CEO) of ePD. He is primarily responsible for new business development, client relations, and oversight of all scientific and business activities at ePD. Don received a Pharm.D. and Ph.D. degree in Pharmaceutical Sciences from the State University of New York (SUNY) at Buffalo. Don has accumulated 15+ years of experience in partnering with pharmaceutical companies, the FDA, and research institutes on applications of pharmacometric and systems modeling in drug development and pharmacotherapy. Don has contributed to over 130 peer-reviewed publications and brings a unique and global perspective to developing pharmacometric and systems-based strategies in drug development and understanding sources of individual and population-level variability in drug responses. Don is a Professor of Pharmaceutical Sciences at SUNY at Buffalo and has served as a Visiting Professor at the University Paris Descartes from 2007 to 2013. He currently serves on the Pharmaceutical Sciences and Clinical Pharmacology Advisory Committee to the FDA and as an expert member of the Board of Pharmaceutical Sciences at FIP. Don also serves as an Associate or Consulting Editor at CPT:Pharmacometrics & Systems Pharmacology (CPT:PSP), and Pharmacology, Research & Perspectives (PRP). Don is a Fellow and Past-President of the International Society of Pharmacometrics (ISoP) and is a Fellow and will be President-Elect of the American College of Clinical Pharmacology (ACCP). Don is also a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the American Association for the Advancement of Science (AAAS).
|Sheila Magil, PhD||BDO USA LLP|
Managing Director, Industry Special Services
Sheila Magil has over 20 years of experience in quality and analytical method development for biologics, peptides and small molecules. Her expertise includes quality assurance, protein and peptide biochemistry and analytical development. She was formerly Senior Manager of Analytical Development and Quality Control at Biomeasure, Inc., and previously held positions at Waratah Pharma, Alkermes, Bion and HHMI at Massachusetts General Hospital. Dr. Magil has implemented quality systems and has managed external analytical and QC activities for multiple biopharmaceutical products. Dr. Magil holds a PhD in Biochemistry from the University of Minnesota.
|Maksim Max Mamonkin||Baylor College of Medicine|
Assistant Professor Pathology & Immunology, Center for Cell & Gene Therapy
Dr Mamonkin is a faculty member at the Center for Cell and Gene Therapy at Baylor College of Medicine. The primary focus of his laboratory is development of novel therapeutic platforms for patients with difficult-to-treat hematologic malignancies and alloimmune complications.
Head, ADC Analytical Skill Center, Biologics Developmentelopment
Delphine MATHIEU joined Sanofi in 2008 where she held different roles within Analytical development teams dedicated to Biologics before focusing on Antibody Drug Conjugates in 2016 by taking the responsibility of the ADC analytical skill center. Prior to Sanofi, she worked for 4 years in a toxicological CRO where she held the role of bioanalytical study director. Delphine holds a masters degree from a French engineering school and completed her course with a PhD in medicinal chemistry obtained from Paris V University.
|Patrick Mayes||Incyte Corp|
Executive Director & Head, IO Antibody Research
Patrick Mayes, PhD, is Executive Director, Head of Biotherapeutic Research at Incyte. Dr. Mayes was previously Director of Biology and was an Early Development Leader for the Immuno-Oncology and Combinations discovery performance unit at GlaxoSmithKline. He has developed novel therapeutic antibodies which modulate innate and adaptive immune responses utilizing a variety of biotherapeutic platforms including Fc-engineered monoclonal antibodies (mAbs), bi-specific mAbs, domain antibodies (dAbs) and antibody-drug conjugates (ADCs) and has initiated and lead programs combining immune targeted therapies as well as others combining immunotherapies with tumor targeted agents.
|Jennifer Maynard, PhD||University of Texas Austin|
Associate Professor, Chemical Engineering
Professor Maynard received her undergraduate degree in Human Biology from Stanford University, followed by a PhD in Chemical Engineering from the University of Texas at Austin, and post-doctoral studies at Stanford University. She returned to the UT Austin as a faculty member in the Department of Chemical Engineering in 2007. Her research group aims to develop advanced antibody therapeutics to treat infectious diseases, using a combination of biological and engineering principles. Her group has developed antibodies to prevent and treat pertussis and shown that these are highly protective in adolescent and neonatal baboon models of disease. Newer work is focused on strategies to re-direct T cells to eliminate virally-infected cells.
|John McCafferty, PhD||IONTAS|
CEO & Founder
John McCafferty was one of the founders of Cambridge Antibody Technology (CAT, now Medimmune) in 1990 and published the first paper/patent describing antibody phage display. After 12 years at CAT he returned to academia at the Sanger Institute and the University of Cambridge. In 2012 John formed IONTAS, a small innovative biotechnology company using phage display to develop novel antibody therapeutics. IONTAS have also developed a novel technology for construction of very libraries in mammalian cells by using CRISPR/Cas 9 and TALE nucleases to efficiently direct the integration of a library of antibody genes into single genomic locus within a population of cells.
|Charlotte McDonagh||Magenta Therapeutics|
Vice President & Head, Biotherapeutics
Charlotte McDonagh joined Magenta Therapeutics in 2017 as Head of Biotherapeutics. She previously served as a vice president at Merrimack Pharmaceuticals, where she led discovery and early clinical stage programs. Prior to joining Merrimack, she led therapeutic antibody selection and engineering projects at Seattle Genetics. Charlotte holds a doctorate in biochemistry from the University of Leicester, U.K, and an undergraduate degree in biochemistry from the University of Bristol, U.K.
|James McNally||CRISPR Therapeutics|
Executive Director & Head, Research & Clinical Assays
Jim McNally is Head of Research, Preclinical and Clinical Assays, CRISPR Therapeutics. He gained extensive experience in immunogenicity strategy, bioanalytical support and scientific oversight of outsourcing of large molecule programs at EMD Serono and at Shire. Previously, he was the lead of the Clinical Assay Development, Validation and Testing bioanalytical group at Pfizer based in Andover, MA. The group was responsible primarily for developing assays to support pharmacokinetic and immunogenicity analysis of the Pfizer large molecule portfolio. Prior to joining Pfizer in 2010, Jim held similar roles in the Clinical Lab Sciences group at Genzyme and Immunobiology group at Repligen. A graduate of the Microbiology and Virology Ph.D. program at LSU Medical Center in 1998, Jim has a special interest in immunomodulation and immunogenicity of biotherapeutics.
Senior Principal Research Scientist
Mike obtained his PhD in Chemistry from the University of Edinburgh in Prof. Bob Baxter’s lab and then moved to Brown University in RI to pursue postdoctoral research with Prof. David Cane on engineering polyketide synthases to produce “unnatural” natural products. He was an early employee of the biotech company Phylos Inc., founded by Brian Seed and Nobel Laureate Jack Szostak to advance the utility of mRNA display in the discovery of high affinity binding proteins through in vitro selection. There he successfully applied mRNA display towards the identification of drug-binding proteins using tissue-derived libraries. Since joining Abbott Laboratories in 2004 and now AbbVie, he has helped provide key molecular/cellular pharmacology support and project leadership to both small molecule and biologics drug discovery programs within Immunology Discovery. He currently leads a group within Global Biologics Discovery that is focused on the identification of novel biologic therapeutics to treat patients with cancer, autoimmune disease or neurological disorders.
|Jonathan Mehtala||Malvern Panalytical|
Tech Specialist, Nanosight
No bio available
|Jan Joseph Melenhorst||University of Pennsylvania|
Director & Adjunct Associate Professor, Pathology & Lab Medicine
Dr. Jan Joseph (Jos) Melenhorst obtained his PhD at the LUMC (Department of Hematology) on the pathogenesis of Aplastic Anemia. In 1998 he moved to Bethesda, Maryland, where he did his research ‐ first as a postdoc, later as a staff scientist ‐ in the laboratory of Dr. John Barrett at the National Institutes of Health, on the immunobiology of marrow failure syndromes, leukemic disorders, and allogeneic stem cell transplantation. In 2012 he was recruited by Dr. Bruce Levine and Dr. Carl June to the University of Pennsylvania, first as Deputy Director of their clinical manufacturing (cGMP) facility. After a year he was promoted to Director of Product Development & Correlative Sciences. In this role, he was at the cusp of the first ever CAR T cell therapy approved by FDA: Kymriah. Dr. Melenhorst is interested in understanding and improving the anti-tumor efficacy and safety of adoptively transferred chimeric antigen receptor-modified T cells through correlative, mechanistic, and functional genomics approaches.
Investigator, BPRD CI
No bio available
|Julija Mezhyrova, MSc||JW Goethe University|
Julija Mezhyrova studied Biochemistry at the Goethe University Frankfurt and gained additional practical experience at the Paul Ehrlich Institute in Darmstadt and at Harvard Medical School in Boston. She is currently working on her PhD thesis at the Goethe University Frankfurt at the Institute of Biophysical Chemistry. Focus of her thesis is the characterization of bacteriolytic phage proteins, being promising targets for future antibiotic development and for industrial applications in the vaccination of livestock.
|Francois-Thomas Michaud||Feldan Therapeutics|
Dr. François-Thomas Michaud co-founded and became CEO of Feldan in 2007 while completing his PhD degree in chemical engineering at Laval University. Through the years, Dr. Michaud and his team worked on a research project that led to the inception of a cell-penetrating proprietary technology, the Feldan Shuttle. This technology, which gives access to a wide range of intracellular therapeutic targets, has the potential to bring a whole new class of therapies to the clinic. Over the years, Dr. Michaud’s value-creating vision shaped the business model of the company, at the center of which resides the Feldan Shuttle.
Through his leadership, exceptional human qualities and determination, Dr. Michaud has successfully built in Québec City a sustainable organization that today stands alongside biopharmaceutical global leaders. In addition to position itself as one of the top Canadian SMI-biotech leaders, Dr. Michaud is actively engaged in the business, academic and entrepreneurial communities of the Province of Québec as an administrator, speaker and mentor.
|Jeffrey Miller||University Of Minnesota Twin Cities|
Professor, Masonic Cancer Center
Jeffrey S. Miller, MD, is currently a Professor of Medicine at the University of Minnesota, Deputy Director of the Masonic Cancer Center, and is in the Division of Hematology, Oncology and Transplantation. Dr. Miller was the recipient of the National Cancer Institute Outstanding Investigator Award for 2015 and has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 200 peer-reviewed publications.
|Mark Milton||Novartis Institutes for BioMedical Research Inc|
Head Ophthalmology Therapeutics
No bio available
|Nora Mineva, PhD||Adecto Pharmaceuticals|
Dr. Nora Mineva is the Chief Scientific Officer and a co-founder of Adecto Pharmaceuticals, a start-up developing the first targeted treatment against ADAM8-positive cancers and a companion diagnostic to identify patients who can benefit from it, with a focus on triple-negative breast cancer as the first indication. She holds a Ph.D. in Pathology and Laboratory Medicine from Boston University School of Medicine and a B.A./M.A. in Biology from Clark University. Dr. Mineva is involved in company management, business development, investor relations, and fundraising efforts in addition to therapeutic and diagnostic development. She is a graduate of the NIH I-Corps Business Training Program and MassBio’s MassConnect Entrepreneur Mentorship Program.
|Shahram Misaghi, PhD||Genentech Inc|
Senior Scientist, Early Stage Cell Culture
I am a senior scientist at the Cell Culture department in Genentech. I have been in this role since 2010. My research involves improving/innovating processes that result in generation of cell lines expressing bio-therapeutics (proteins and antibodies used as drugs) that grow better and yield higher titers with better product quality attributes. Bachelor: University of California Berkeley, Molecular and Cell Biology. PhD: Harvard University, in Biological and Biomedical Sciences. Post-doctoral fellow at Massachusetts Institute of Technology (MIT). Post-doctoral fellow at Genentech.
|Carl Morris||Solid Biosciences|
Prior to joining Solid, Dr. Morris was a Senior Director for Pfizer’s Rare Disease Research Unit, leading their efforts in neurologic diseases and the muscle biology programs. While at Pfizer, Dr. Morris directed several small molecule and biotherapeutic development programs, including a program that led to a Phase 2 study in Duchenne Muscular Dystrophy, while also heading an internal research group responsible for advancing programs from target identification to the clinic for many of the rare neurologic and muscle-related diseases. Dr. Morris identified key external opportunities and worked closely with patient groups, academic laboratories, and other industry partners to advance drug development in the rare neuromuscular space. His scientific and drug development experience at Pfizer also included investigations into broader muscle wasting conditions, as well as tendon and bone repair biology. Prior to joining Pfizer in 2007, Dr. Morris was an Assistant Professor at Boston University School of Medicine and a founding faculty member of the Muscle and Aging Research Unit, established to investigate strategies for improving muscle function during aging or disease. He completed his Postdoctoral fellowship in the Department of Physiology at the University of Pennsylvania where he worked on multiple projects ranging from molecular aspects of muscle protein interactions through to therapeutic approaches for modulating muscle size and function. As a trained muscle physiologist, his academic pursuits have ranged from biophysical aspects of muscle contraction and enzyme kinetics to therapeutic interventions in a variety of in vivo muscle atrophy and disease models. Dr. Morris holds a B.A. in Biology from Franklin Pierce College (Rindge, NH) and a PhD in Physiology from UCLA.
Director, Regulatory Affairs
William leads the orphan drug unit within GRA and serves as the US Agent for multiple Investigation of New Drugs, New Drug Applications and Supplements. William provides strategic advice to clients on regulatory strategy, leads regulatory projects and specialty designation requests, provides CMC technical writing and reviews for new applications (INDs, NDAs, BLAs) in rare disease space; interacts with Regulatory Agencies (FDA, Heath Canada, etc.) He has also served as the Regulatory Project lead for numerous NDA 505(b)(2) applications approved by the US FDA.
William has prepared NDA 505(b)(2), INDs, supplements and life cycle management submissions (in eCTD) with an emphasis in CMC for NDAs and INDs. He has provided RA Assessments for change control for pharmaceutical products ensuring regulatory compliance, as well as CMC strategies as they relate to new applications and supplements. He has completed GAP analyses as they relate to CMC content. William is familiar with the requirements for pharmaceutical labelling to ensure that it is sufficient for submission to FDA (container labels, package inserts and metadata for SPL format). He has knowledge of regulations in Asia Pacific and Latin America for both pharmaceuticals and medical devices.
|Dafne Mueller, PhD||University Of Stuttgart|
Group Leader, Biomedical Engineering
Dafne Müller received her doctoral degree from the University of Stuttgart in Germany. At the present she holds a group leader/lecturer position at the department of Biomedical Engineering at the Institute of Cell Biology and Immunology of the University of Stuttgart. Working in the field of recombinant antibodies for over 15 years, her current research focuses on the development of recombinant antibody-fusion proteins with immune stimulatory or costimulatory properties for targeted cancer immunotherapy.
|Alexander Muik||BioNTech AG|
No Bio available
|Idris Mustafa, MS||Genentech Inc|
Lead Automation Scientist, BioMolecular Resources
Idris Mustafa is a Lead Automation Scientist and Software Architect, currently residing in the San Francisco Bay Area, leading departmental automation efforts within the Biomolecular Resources Organization at Genentech, a member of the Roche Group. Idris has spent the last 10 years bridging the gap between drug discovery and technology using advanced control machines, building custom algorithms, and expanding his breadth of knowledge. He has also dedicated much of his career to creating software products that increase efficiency in the lab and change the face of the way robots, databases and people interact. Idris' research is at the cutting edge of liquid-handling robotics innovation; leveraging 3D-printing technologies and machine learning concepts to drive productivity. Idris believes his "Faith in God and passion to optimize the human condition", will inevitably lead to future breakthroughs in the world of science and technology.
|Mahmoud Nasr, PhD||Harvard Medical School|
Instructor, Biological Chemistry & Molecular Pharmacology
I received a PhD in pharmaceutical Sciences from Northeastern University, and postdoc fellowship training at Harvard Medical School. Currently, I’m a group leader at Brigham and Women’s hospital in the Engineering in Medicine Division, Department of Medicine.
|Horacio Nastri, PhD||Incyte Corp|
Executive Director Antibody Discovery
No bio available
|Madhusudan Natarajan, PhD||Shire HGT a member of the Takeda Group|
Head, Rare Genetic Disease Research
Madhu is currently the Head of the Rare Diseases Drug Discovery Unit in Research at Takeda, and his group’s mandate spans ideation through to development of molecules to take into the clinic. Madhu has been working on discovery programs in rare diseases for almost a decade at Shire. In previous roles Madhu was Pfizer, and as faculty at the University of Texas Southwestern Medical Center in Dallas. Madhu holds a Baccalaureate in Electronics and Telecommunications Engineering from the University of Madras, India, and a doctorate in Neurobiology from Northwestern University, Illinois.
|Paul Neeson||Peter MacCallum Cancer Center|
Group Leader & Associate Professor, Cancer Immunology
Paul Neeson completed a PhD at the University of Melbourne (Pathology), before doing a post-doc in the Paterson lab (University of Pennsylvania) where he worked on B-cell lymphoma vaccines. He returned to Melbourne and established the human immunology translational lab (HITRL) in Cancer Immunology Research at the Peter MacCallum Cancer Centre. The Lab’s focus is on chimeric antigen receptor (CAR) T cells for solid tumors and human immuno-oncology. His lab has adopted ‘state of the art’ technologies to explore the immune context of human cancer. This information is being used to better understand immune escape, to stratify patients for immunotherapy combination treatments (including CART cells) for better outcomes in patients with solid tumors
No bio available
|Dario Neri||ETH Zurich (Swiss Federal Institute of Technology)|
Prof, Chemistry and Applied Biosciences
Dario Neri was born in Rome on 1 May 1963, but grew up in Siena (Italy). He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich (Nobel Prize Chemistry 2002). After a post-doctoral research internship (1992-1996) at the Medical Research Council Centre in Cambridge (UK), under the supervision of Sir Gregory Winter (Nobel Prize Chemistry 2018), he became professor at ETH Zürich in 1996. Dario Neri is currently Full Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, ETH Zürich. The research of the Neri group focuses on the engineering of therapeutic antibodies for the therapy of cancer and other angiogenesis-related disorders and on the development of DNA-encoded chemical libraries. Dario Neri is a co-founder of Philogen (www.philogen.com), a Swiss-Italian biotech company which has brought various antibody products into multicenter clinical trials for the treatment of cancer and of chronic inflammatory conditions. Dario Neri has published more than 400 articles in peer-reviewed scientific journals. He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, of the Mangia d’Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer of the French Medicinal Chemistry Society in 2011, of the Phoenix Prize 2014 and of an ERC Advanced Grant in 2015.
|Anton Neschadim||ImmunoBiochem Corp|
President & CEO
Anton is a biomedical professional, scientist, innovator, entrepreneur and venture capitalist with more than 15 years of industry and academic experience in research and drug development. At ImmunoBiochem Corporation, Anton is leading the development of a new class of tumor microenvironment-targeted anti-cancer therapeutics. Anton was formerly the Director of Drug Development at Armour Therapeutics Inc., a biopharmaceutical company developing a new class of anti-cancer therapeutics for prostate, breast and ovarian cancers. Throughout his career, Anton worked on R&D and consulting projects with several biopharmaceutical companies developing biological therapeutics and immunotherapies in oncology. Anton has expertise in cancer research, immunology, chemistry, regenerative medicine and gene therapy, and authored more than 25 peer-reviewed publications and patents. Anton obtained his PhD, MSc, and Hon. BSc degrees in medical biophysics, immunology, and biological chemistry at the University of Toronto, where he also completed postdoctoral work and his MBA at the Rotman School of Management. Anton was also a trainee of the CIHR Training Program in Regenerative Medicine (TPRM), Toronto General Hospital, University Health Network. Anton was a founding board member, and former CCO and organizing committee member of the Canadian Science Policy Centre (Toronto, ON) – a national organization promoting science policy in Canada. Anton has led several venture capital investments in biomedical and healthcare companies at GreenSky Capital.
|Ho Leung Ng, PhD||Kansas State University|
Associate Professor, Biochemistry & Molecular Biophysics
Ho Leung Ng completed his BA at Harvard University, PhD at UCLA, and postdoctoral fellowship at UC Berkeley in the areas of structural biology and crystallography. After leaving UC Berkeley, Dr. Ng worked with Brian Kobilka at ConfometRx on GPCR crystallography. Dr. Ng then moved to the University of Hawaii as an Assistant Professor and later to Kansas State University as Associate Professor. His current research focuses on experimental and computational structure-based drug design for GPCRs, nuclear receptors, and kinases. Dr. Ng is also interested in applications of machine learning for chemistry and drug design.
|Jens Niewoehner||Roche Innovation Center Penzberg|
Senior Principal Scientist, Research & Early Development
Jens Niewoehner obtained his Ph.D. at the Max-Planck-Institute for Cell Biology in Martinsried/Germany. Following a PostDoc at the Curie Institute in Paris, he worked for two Biotech start-ups in the Munich area before joining Roche Pharmaceutical Research and Early Development (pRED) in 2006. With his group, he is developing cellular functional assays for biotherapeutics characterization and screening. Since several years, he is actively involved in driving the development of the Roche Brain Shuttle platform to enable brain uptake of large-molecule drugs.
|Knut Niss||Mustang Bio Inc|
Chief Technology Officer
Dr. Knut Niss, Ph.D. has been Chief Technology Officer at Mustang Bio, Inc. since March 2018. He joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He also served as Senior R&D Program Manager at EMD Millipore, where he established processes for the large-scale expansion of adult and pluripotent stem cells. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. He holds a Ph.D. in molecular biology from Humboldt University of Berlin, and an M.S. in microbiology from the University of Göttingen in Germany. Dr. Niss completed his postdoctoral research at Boston Children’s Hospital and the Dana-Farber Cancer Institute.
|Andrew Nixon, PhD||Boehringer Ingelheim Pharmaceuticals Inc|
Vice President Biotherapeutics Molecule Discovery
Dr. Nixon currently is Vice President of Biotherapeutics Molecule Discovery at Boehringer Ingelheim. In this role, he is responsible for early biologic discovery activities. Prior to joining Boehringer Ingelheim, Andy spent 17 years at Dyax including four years as Head of Research and most recently was at Magenta Therapeutics a stem cell transplant company. At Dyax, he focused on biologic drug discovery including peptides, small proteins and antibodies across multiple therapeutic areas including oncology and inflammation. He was a key scientific partner for Dyax’s Licensing and Funded Research Program (LFRP), contributed to numerous antibodies in clinical studies including Avelumab, an anti-PD-L1 antibody and Opicinumab, an anti-Lingo-1 antibody and led from discovery to IND Takhzyro, a plasma kallikrein inhibitory antibody that was approved in 2018.
Dr. Maureen O’Connor-McCourt brings her TGF-beta expertise, which began in her post-doctoral training in the laboratory of Drs. Michael Sporn and Anita Roberts, to Forbius as Chief Scientific Officer. She has published over 100 peer-reviewed manuscripts, including over 50 publications in the TGF-β field. Maureen is an expert in the discovery and development of targeted biological therapies. Prior to joining Forbius, Maureen was Principal Research Officer and Section Leader at the Canadian National Research Council (NRC). While at NRC, Maureen served as a Scientific Leader of NRC's Biologics Program, a pan-Canadian network of over 10 research teams. Under her leadership, this program established a successful track record in developing innovative protein therapeutics.
|Daniel Olive||Aix Marseille University|
Head Tumor Immunology
D. Olive has been a pioneer and leader in the co-signalling field since 1990. His work is dedicated to tumor immunology with a major emphasis on innate immunity and co-signalling molecules. Selected major breakthroughs: 1) Identification of signaling pathways involved in CD28 and ICOS costimulatory molecules; 2) Demonstration that BTN3A1/CD277 is a major inducer of Vg9Vd2 response; 3) identification of the function of BTLA and HVEM in the regulation of immune function; 4) Identification of molecular mechanisms associated to NK cells impairment in AML patients; 5) first identification of alteration of NK cells in the tumor bed in breast and prostate cancer; 6) First in man clinical trial using anti-KIR mAbs in AML patients; 7) Deciphering of of ICOS ICOSL interaction in the regulation of Tregs in lymphomas.
|Catherine Owczarek, PhD||CSL Ltd|
Dr Catherine Owczarek is the Director of the Recombinant Protein Expression Group (CSL Limited) located at the Bio21 Institute in Melbourne, Australia. After gaining a PhD at the John Curtin School of Medical Research, Canberra, she completed her post-doctoral studies at the Sir William Dunn School of Pathology in Oxford, the Walter and Eliza Hall Institute in Melbourne and then was a Senior Research Fellow at the Monash Institute of Medical Research in Melbourne. Since joining CSL Limited Catherine has led the CSL Research Group’s efforts in the successful development of programs producing mammalian-derived recombinant proteins using transient expression systems. She is involved in a range of CSL’s early phase drug discovery and development campaigns and has experience in early development clinical development programs of therapeutics for the prevention and/or treatment of human diseases.
Scientist I, Antibody Discovery
Christina has been a core member of the Antibody Discovery team within Biologics Drug Discovery for over 10 years. She graduated from MIT with a BA in Chemical Engineering and a MA in Bioengineering from the University of Pennsylvania. She has extensive experience working with phage and yeast display systems, including the Dyax and Adimab platforms. She has led numerous Antibody Discovery campaigns for a variety of targets, including therapeutic candidates for oncology, autoimmune disease, fibrosis, MS, and neurological indications.
|Paul Parren, PhD||Lava Therapeutics|
Executive Vice President & Head
Prof. Paul W.H.I. Parren, (Lava therapeutics) is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. Prof. Parren studied Biology at the University of Amsterdam where he obtained a M.Sc. in Experimental Oncology (cum laude) in 1987 and a PhD in 1992. Next, he was a Postdoc, Assistant Professor and Associate Professor in the department of Immunology at The Scripps Research Institute in La Jolla, California, where he interrogated the human antibody response in protection against viral infections. From 2002-2017, he served in the positions of Vice President, Senior Vice President and Scientific Director at the biotechnology company Genmab in Utrecht, where he headed preclinical R&D leading to the development of the approved therapeutic antibodies ofatumumab (Arzerra) and daratumumab (DARZALEX), and several clinically translated technologies aimed at improving antibody therapy including bispecific and effector-function enhanced antibodies. In 2015, he became a Professor of Molecular Immunology at the Leiden University Medical Center in Leiden. Since 2018, he is EVP and head of R&D at the biotech Lava Therapeutics where he develops novel bispecificT-cell engagers for cancer therapy. He also provides drug development, patent and investment advice as an independent biotech consultant.
|Saleha Patel, PhD||AstraZeneca|
Senior Research Scientist, Protein Science & Discovery Biology
Since joining AstraZeneca in 2017, Saleha has worked on and produced high quality protein reagents for a number of early discovery projects. Her specific focus within the team is in the area of protein QC and sample preparation for specialist downstream applications. More recently, she has been developing and prosecuting biochemical assay strategies for screening and hit dicovery. Prior to joining AstraZeneca, Saleha studied Biochemistry at the University of York, followed by an MSc in Bioscience Technology with a short time also spent at CRUK at the London Research Institute. She completed her PhD and first Postdoc at the University of Leicester in partnership with UCB Pharma. Her work looked into characterising the structures and function of antagonists of the Wnt signalling pathway using NMR, EM and several other biophysical techniques.
|Sofie Pattijn||ImmunXperts SA|
Founder & CTO
Sofie Pattijn (CTO and founder, ImmunXperts) has over 20 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development. She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.
|Pedro Paz||Bayer HealthCare Pharmaceuticals|
Senior Staff Scientist, Molecular & Cellular Immunology Biologics Research
Pedro E. Paz, PhD heads the Immunoprofiling Group in Biologics Research at Bayer Pharmaceuticals. He received both undergraduate and graduate degrees in Molecular Cell Biology- Immunology from University of California - Berkeley. He is responsible for the immunogenicity assessment of biotherapeutics in the drug development pipeline.
|Robert Pejchal, PhD||Adimab LLC|
Associate Director Antibody Engineering
I received my PhD from University of Michigan Ann Arbor in protein crystallography. I then did a postdoc at The Scripps Research Institute where I studied broadly neutralizing HIV-1 antibodies, solved crystal structures of such antibodies bound to viral envelope glycoproteins and peptide antigens. After taking a scientist position at Adimab LLC, my focus on antibody engineering blossomed into a bispecific antibody discovery and optimization and cell selection approaches for membrane protein targets. Currently, as Director of Antibody Engineering, my work on bispecifics and membrane protein targets continues alongside platform optimization, antibody format research and development, and developability.
|Kate Peng||Genentech Inc|
Senior Scientist, Assay Developmentelopment & Technology
Dr. Kate Peng received her Ph.D. in metabolic biology from the University of California Berkeley. Following her post-doctoral training at Berkeley, Dr. Peng worked at biotechnology industry with a focus on developing cell-based methods for high-throughput screening of drug candidates targeting GPCRs. Dr. Peng joined Genentech in 2007 and is currently a Group Leader/Senior Scientist in the Department of BioAnalytical Sciences. Her focus is on development of bioanalytical strategies and methods to enable assessment of the pharmacokinetics, pharmacodynamics, immunogenicity of protein therapeutics from early development to clinical as well as post-marketing stages. Dr. Peng has led bioanalytical effort for supporting the development of protein therapeutics that target cancer immunotherapy, immunology, neurology and cardiovascular disease areas.
|Li Peng, PhD||Palleon Pharmaceuticals|
Senior Vice President, Research and Early Product Development
Li Peng is Senior Vice President of Research and Early Product Development at Palleon Pharmaceuticals, a leading biotechnology company focused on developing Glyco-Immune Checkpoint therapeutics to treat cancer. Li led the invention of two core platform technologies at Palleon – the EAGLE platform for targeting glyco-immune checkpoint ligands and the HYDRA platform for enabling patient stratification. Previously, she worked at Medimmune/AstraZeneca for ~10 years with increasing responsibilities from antibody engineering and characterization to leading drug discovery programs and cross-functional project teams. Li has a PhD in Biochemistry, MS in Genetics, and BS in Biology. She has published ~30 papers and authored >10 patents and applications.
Lead Microbiology Associate, Analytical Developmentelopment
Michele Perry received her Bachelor of Science degree in Biology and Biotechnology from Worcester Polytechnic Institute. She has ten years of experience in the science field including quality control, DMPK, manufacturing, and research and development at companies such as Seres Therapeutics and T2 Biosystems. Most recently, Michele has been developing release assays for live bacterial products in the Analytical Development group at Synlogic, Inc.
|Theodore Peters, PhD||Seattle Genetics|
Senior Scientist, Cell Line Developmentelopment
I received my doctorate from the University of Colorado Health Sciences Center focusing on protein aggregation; and did my post-doc at the Buck Institute. My work in the Cell Line Development Group involves media and process development, engineering novel DNA vectors, and cell line evolution.
|Oleh Petriv, PhD||AbCheck|
Vice President, New Technology Development
Dr. Oleh Petriv received his PhD in Cell Biology at the University of Alberta in Canada. Later he studied design and manufacturing of microfluidic chips, worked on high-throughput single-cell PCR and sequencing methods. Oleh is one of the co-founders of AbCellera, a company focusing on monoclonal antibody discovery based in Canada. In 2018 he brought his experience of R&D and technology development to AbCheck and leads a team developing entirely new and unsurpassed methods of antibody discovery by functional criteria.
|Kelli Phillips||PPD Inc|
Kelli Phillips began her career in biologics in 2006, as a principal investigator in the Immunochemistry Research and Development department at PPD. In her current role as manager, she provides oversight to method development and validation for quantitative (PK), immunogenicity (ADA) and neutralizing antibody (NAb) methods. During her tenure at PPD, her focus has been on the development of robust, drug-tolerant immunogenicity assays, life-cycle management of extended-use methods and strategies for biosimilar method validations.
|Diana Pippig||Roche Innovation Center Penzberg|
Group Leader, Functional Characterization
Dr. Diana Pippig is a Senior Scientist and Team Leader in the Functional Characterization Department within Roche Pharma Research and Early Development, Large Molecule Research, at Roche Innovation Center Munich. Among her responsibilities are all aspects of target:lead interaction characterization by means of SPR and other biophysical methods, where she supports projects throughout e.g. lead identification, developability assessment as well as QC assay development. Driving new method development, she is particularly focusing on new approaches in data evaluation to gain deeper and faster understanding of structure/function relationship of complex biologics. She further supports diverse next generation biologics projects as technical project leader or analytics expert. Diana holds a PhD in Biochemistry from the Ludwig Maximilians University of Munich and did a PostDoc in Biophysics at the LMU, before joining Roche in 2011.
|Simon Plyte, PhD||Merus NV|
Vice President Immune Oncology
Dr. Plyte is Vice President of Immune Oncology at Merus N.V. in Holland where he is responsible for building a world class pipeline of bispecific antibodies to treat multiple cancers. Using the Merus Biclonics® platform his team are developing bispecific antibodies to many immunological targets for the modulation of the immune system. Prior to Merus, Dr. Plyte was Senior Director of Immune Oncology at Molecular Partners, Switzerland, where his team were using DARPins to modulate immunological targets. At Boehringer Ingelheim, Germany, Dr. Plyte was Director in Cancer Immunology and Immune Modulation where various of his teams worked on the development of biologics to treat cancer, ocular diseases, diabetes and neurodegenerative diseases including the development of a blood brain barrier shuttle. He has over 20 years of experience in the Pharma industry.
Head, Early Discovery
No bio available
Scientific Director, Analytical Developmentelopment
Francis Poulin is a Director of Analytical Development at Sanofi in Framingham, Massachusetts, where he is responsible for the development, qualification and validation of bioassays and molecular assays to support the release of biologics in preclinical and clinical development, including gene therapy products. Prior to joining Sanofi, Francis was a postdoctoral fellow at HHMI/University of California, Berkeley and the Lawrence Berkeley National Laboratory. Francis received his PhD in Biochemistry from McGill University.
|Gabriele Proetzel, PhD||Takeda Pharmaceuticals Inc|
Director, External Neuroscience Innovation, Neuroscience Drug Discovery Unit
In her current role, Dr Proetzel focuses on cell and gene therapy therapeutic approaches for neurological disorders. Prior industry appointments were at Scil Proteins, Halle Germany, Deltagen Inc., San Carlos, California and Boehringer Mannheim/Roche Penzberg, Germany. Before joining Takeda, Gabriele held the position of Associate Director of Technology Transfer at The Jackson Laboratory, Bar Harbor, Maine, USA. Gabriele earned her Masters degree in Life Sciences from the Ludwig-Maximilian University of Würzburg, Germany, and a Ph.D. from University of Cincinnati, Ohio studying homologous recombination in embryonic stem cells to develop mouse models for disease in the laboratory of Prof. Tom Doetschman. She completed her postdoctoral training in the laboratory of Prof. Peter Gruss at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany.
|Laszlo Radvanyi, PhD||Ontario Institute for Cancer Research|
President & Scientific Director
Prior to joining OICR, Dr. Radvanyi was the Senior Vice President and Global Head of the Immuno-Oncology Translational Innovation Platform at EMD Serono (Merck KGaA, Darmstadt, Germany). He also served as a Senior Scientific Advisor for EMD Serono, specializing in immunology and immuno-oncology. While at EMD Serono, Dr. Radvanyi rebuilt and re-organized EMD Serono’s immuno-oncology research platform and rejuvenated the their immuno-oncology research pipeline. He recruited key talent and established influential partnerships with academia that focused on biomarker-driven clinical trials. Notably, Dr. Radvanyi established an alliance between EMD Serono and Pfizer for the development of anti-PD-L1 (avelumab) and co-led EMD Serono’s CAR T-cell program in partnership with Intrexon and Ziopharm. Dr. Radvanyi also has experience in biotech drug discovery and development (founding CSO for Iovance Therapeutics). He is an Associate Editor for the Journal of Immunotherapy for Cancer (JITC), serves on the Keystone Conferences Scientific Advisory Board, and serves on grant review panels for numerous national and international agencies.
|Jonah Rainey, PhD||Gritstone Oncology Inc|
Vice President Antibody Therapeutics
Dr. Jonah Rainey is currently the Vice President for the Antibody Therapeutics department at Gritstone Oncology. Previously, he was the CEO of Oriole, a consulting and research organization focused on discovery through early development of biologic in San Diego. He holds a PhD in Biochemistry from Tufts University and completed postdoctoral training at the University of Wisconsin and the Salk Institute. He has been actively engaged in discovery, research, and development of bispecific antibodies in a biotech setting for 12 years. He is an inventor on several patents and applications describing novel bispecific platforms as well as current clinical candidates that exploit these platforms. Dr. Rainey led or had major contributions to research and early development of at least three current clinical candidates in phase 1 and 2, and led many additional advanced preclinical programs in oncology, infectious disease, autoimmunity, and other therapeutic areas. Industry experience spans small biotech (MacroGenics, MabVax) and large pharma settings (MedImmune/Astrazeneca).
|Sarav Rajan||AstraZeneca Biologics|
Sarav Rajan obtained his PhD from McGill University and a post-doctoral fellowship from the University of Toronto, specializing in the use of phage display to isolate therapeutic antibodies. He has been at AstraZeneca in the department of Antibody Discovery and Protein Engineering for over 7 years where he has earned several distinctions, including company-wide innovation awards. He currently manages a team in Maryland that has pioneered a novel discovery platform that captures and screens the natively-paired antibody repertoire from millions of B cells.
|Theodore Randolph, PhD||University of Colorado Boulder|
Endowed Professor, Chemical & Biological Engineering
Ted Randolph received his Ph.D. in Chemical Engineering at the University of California, Berkeley. He worked as a post-doctoral fellow at the Ecole Polytechnique Federale de Lausanne, and then joined the Department of Chemical Engineering at Yale University as an Assistant Professor. After promotion to Associate Professor, he was named to Yale’s first John J. Lee Junior Professorship Chair in Chemical Engineering. In 1993, Dr. Randolph accepted the Patton Associate Professorship Chair in the Department of Chemical Engineering at the University of Colorado. He currently serves as the Gillespie Professor of Bioengineering, co-Director of the University of Colorado’s Center for Pharmaceutical Biotechnology. Dr. Randolph is a National Science Foundation Presidential Young Investigator, and received the AIChE Professional Progress Award and has twice received the American Pharmacists’ Association Ebert Prize. He is an author of more than 230 peer-reviewed journal articles in the areas of biopharmaceutical formulation, lyophilization of proteins, protein-solvent interactions in non-aqueous environments, and protein refolding. Dr. Randolph is an inventor on 27 US patents, and has cofounded three companies, RxKinetix Inc., Barofold, Inc. and VitriVax Inc.
|Reda Rawi, PhD||NIH NIAID|
2019 – present Staff Scientist, Structural Bioinformatics Core Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
2016 – 2019 Postdoctoral Scientist, Structural Bioinformatics Core Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
2013 – 2016 Postdoctoral Scientist, Qatar Computing Research Institute, Doha, Qatar
2008 – 2014 Centre for Medical Biotechnology, University of Duisburg-Essen, Essen, Germany, PhD
2007 – 2008 Department of Crystallography, Birkbeck College, University of London, London, UK, M.Sc.
2003 – 2007 Department of Mathematics, University of Applied Sciences Koblenz, Remagen, Germany, Diploma Mathematics
|Matthew Raybould, MChem (Oxon.)||University of Oxford|
DPhil Student, Oxford Protein Informatics Group, Department of Statistics
Matthew Raybould received his MChem degree in Chemistry from the University of Oxford in 2016. He is currently studying for a DPhil, working in the Oxford Protein Informatics Group at the University of Oxford under the supervision of Professor Charlotte Deane. He collaborates with AstraZeneca, GSK, Roche, and UCB. He wrote the Therapeutic Structural Antibody Database (Thera-SAbDab) and the Therapeutic Antibody Profiler (TAP) for structure-based developability assessment. He has written reviews on harnessing immunoglobulin sequencing data in therapeutic discovery. His research currently focuses on in silico high throughput antibody screening and subsequent rational optimisation.
|William Redmond||Providence Health & Services|
Director, Immune Monitoring Lab
Dr. Redmond received his undergraduate degree in Biology at the University of California, Davis prior to pursuing a PhD in Immunology at The Scripps Research Institute in La Jolla, CA. His doctoral studies focused on understanding how defects in the regulation of “killer” CD8 T cells can lead to the onset of autoimmune (type 1) diabetes. After obtaining his PhD, Dr. Redmond joined Dr. Andrew Weinberg’s laboratory at the Earle A. Chiles Research Institute (EACRI) at Providence Cancer Institute in Portland, OR. Dr. Redmond’s post-doctoral research focused on tumor immunotherapy, which harnesses the power of the patient’s own immune system to seek out and destroy tumors. Specifically, he investigated the mechanisms by which an agonist anti-OX40 mAb enhanced CD8 T cell function to eradicate tumors. Currently, Dr. Redmond is an Associate Member and Director, Immune Monitoring Laboratory at the EACRI and an Adjunct Assistant Professor in the Department of Molecular Microbiology and Immunology at Oregon Health & Science University. His work seeks to elucidate the mechanisms by which combinatorial approaches to cancer immunotherapy, such as the provision of T cell co-stimulation plus checkpoint blockade augment the development of potent effector CD8 T cells capable of eliminating tumors.
|Janice Reichert, PhD||Antibody Society|
Janice M. Reichert, PhD, is Executive Director of The Antibody Society. She is also the founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development, and co-editor of the Handbook of Therapeutic Antibodies. She has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. Dr. Reichert received her PhD in Chemistry from the University of Pennsylvania and did her post-doctoral training at Harvard Medical School.
Team Leader, Molecular Design & Engineering
Carlos R. Reis has been working in the Protein Engineering field for over 15 years. During this time, he has worked with several small and large biotech companies at different stages of product development, from discovery to manufacturing. His primary focus has been on protein therapeutics, antibody structure-function relationships, protein and antibody design and developability assessment of biologics during early discovery. He is currently a group leader in Antibody Engineering at GSK located in Stevenage, UK, working at the interface between discovery and development on new protein engineering strategies and technologies to optimize the developability profile of candidate molecules and accelerate their development. Carlos R. Reis received his PhD in Mathematics and Natural Sciences from the University of Groningen, NL, and completed his postdoctoral training in computational biology and cell engineering at UT Southwestern Medical Center in Dallas, USA. His main contributions include the development of novel computational protein design methods to generate potent and selective anti-cancer therapeutics targeting TNFR members, the discovery of new regulatory links between therapeutics and endocytic trafficking and the design of novel effector-based protein engineering strategies to restore self-tolerance in autoimmunity. He is passionate about science, mentorship and applying innovative protein design principles to engineer effective therapies that can potentially save lives.
|John Rhoden||Eli Lilly & Co|
Senior Research Scientist
John Rhoden, Ph.D. is a Principal Research Scientist in the Department of Drug Disposition at Eli Lilly and Company. He received his B.S. in Chemical Engineering from N.C. State University and a Ph.D. in Chemical Engineering from M.I.T. under the guidance of Prof. K. Dane Wittrup, after which he joined Eli Lilly and Company in 2012. At Lilly, Dr. Rhoden serves as a large molecule ADME project leader on discovery and early development project teams in a variety of therapeutic areas including oncology, immunooncology, autoimmunity, and kidney disease. Dr. Rhoden’s professional interests lie in using simple mathematical models to understand complex systems, interrogate hypotheses, and guide experiment design and interpretation.
|Ken Riker||Celgene Corp|
Director, Product Quality
Over the last 16 years, Ken Riker has led Quality teams to develop and execute filing strategies for three successful global filings for biologics. Most recently he led the effort to evaluate the risk associated with the integrated control strategy for Celgene’s first cell therapy product. He lives in the Seattle area.
|James Riley||University of Pennsylvania|
Associate Professor, Microbiology
James L. Riley, PhD, is an Associate Professor of Microbiology at the University of Pennsylvania. His lab studies the cell biology and therapeutic use of primary human T cells. His lab has developed and is developing a number of T cell-based therapies to treat HIV, cancer and autoimmune diseases. As an officer in the US Army, he received postdoctoral training in Dr. Carl June’s laboratory, where he developed an interested in T cell signaling pathways and therapeutic uses of primary human T cells. Dr. Riley graduated from Vanderbilt University with a BS in Molecular Biology, studying Dictyostelium iscoideum, and subsequently earned his PhD from Emory University in Dr. Jeremy Boss’ laboratory, studying the gene regulation of MHC class II genes.
|Jesse Rinehart, PhD||Yale University|
Assistant Professor, Physiology
Dr. Jesse Rinehart is an Associate Professor with tenure in the Department of Cellular & Molecular Physiology at the Yale University School of Medicine with a joint appointment in the Systems Biology Institute. Dr. Rinehart’s research aims to understand and “decode” the roles of protein phosphorylation in humans. His laboratory uses an innovative combination of quantitative phosphoproteomics and synthetic biology study protein phosphorylation in single proteins and protein networks. Recently, research in Dr. Rinehart’s laboratory has been accelerated by their Escherichia coli based technologies that enable site-specific incorporation of phosphoryation into human proteins. Dr. Rinehart received his PhD in Molecular Biophysics and Biochemistry from Yale in 2005. He studied protein synthesis and the evolution of the genetic code during his graduate work. His did his postdoctoral research with Richard Lifton in the Department of Genetics at Yale and focused on protein phosphorylation in physiological systems.
|Aaron Ring, MD, PhD||Yale University|
Assistant Professor, Immunobiology
Aaron Ring received his undergraduate training at Yale University and entered the Stanford Medical Scientist Training Program for his MD and PhD degrees. At Stanford, he worked in the laboratories of K. Christopher Garcia and Irving Weissman to use structure-based protein engineering to develop new cytokine and immune checkpoint therapies for cancer. He additionally developed novel methodologies in protein engineering to create biologic agents against challenging targets such as G protein coupled receptors (GPCRs). Aaron joined the faculty of the Yale Department of Immunobiology in 2016 as the Robert T. McCluskey Yale Scholar. The focus of his research is to understand and manipulate the activity of immune receptors using structural and combinatorial biology approaches.
|Frank Riske, PhD||BDO USA LLP|
Managing Director, Bioprocess Technology Group
Frank J Riske, Ph.D., has over 30 years of experience in the biopharmaceutical industry and has been involved in the development, or improvement, of eight commercial protein products. Prior to joining BPTC four years ago (and more recently the BioProcess Technology Group at BDO; after BPTC acquisition), Dr. Riske was a Senior Director in the Late Phase Process Development Group at Genzyme, a Sanofi company. At Genzyme, Dr. Riske was responsible for the development of late stage downstream processes for recombinant enzymes, monoclonal antibodies, Adenovirus (gene therapy) and the identification and exploration of new technologies, including continuous processing, to streamline and improve purification. Prior to joining Genzyme, Dr. Riske managed the development, implementation and manufacture of a peptide bound within a novel sustained release vehicle, and the development of a next generation process to purify IVIG from plasma (both at Epic Therapeutics). Before Epic, Dr. Riske held positions at Repligen and Hoffmann-LaRoche during which he developed and improved, downstream processes for proteins produced in mammalian cell culture, E coli, and Pichia systems. Dr. Riske was also responsible for the manufacture of MAb fragments at Repligen. Dr. Riske has published over twenty peer reviewed papers and patents and is active in the scientific community as both a mentor to young scientists and as a conference speaker and organizer. Dr. Riske received his B.S. in Biology from Fairfield University, Ph.D. in Biochemistry and Microbiology from Rutgers University and completed a post-doctoral position at Hoffmann-LaRoche.
|Wendy Ritacco||Abbvie Bioresearch Center|
Senior Scientist III, Global Biologics
Wendy Ritacco is a Senior Scientist at Abbvie and specializes in design and optimization of conditionally activated biologics. She dedicated to the creation of efficacious treatments without deleterious side effects. She received her MS from Worcester Polytechnic Institute and has more than 25 years biopharmaceutical industry experience.
|Nathan Robertson, PhD||OXGENE|
Group Leader, Antibody Discovery Team
Nathan is Group Leader of the Antibody Discovery team at OXGENE. His team works towards the development of novel mammalian display technologies. Before joining OXGENE, Nathan was Principal Scientist at Heptares Therapeutics and a postdoctoral researcher at the ICR. Prior to this, Nathan earned his PhD in Biophysics at Imperial College London.
|Anne Skaja Robinson, PhD||Carnegie Mellon University|
Professor & Head, Chemical Engineering
Anne Skaja Robinson became Head of Carnegie Mellon University’s Department of Chemical Engineering in 2018. Prior to that, she she served as Chair of Chemical and Biomolecular Engineering at Tulane University for six years, and formerly held the position of Full Professor and Associate Chair at the University of Delaware. Having received both her B.S. and M.S. in Chemical Engineering from Johns Hopkins University, and her PhD in Chemical Engineering from the University of Illinois at Urbana-Champaign, Robinson has earned many honors, including a DuPont Young Professor Award, and a National Science Foundation Presidential Early Career Award for Science and Engineering. She is also a fellow of both the American Institute for Medical and Biological Engineering, and the American Institute of Chemical Engineers.
|Lucie Rochard, PhD||Massachusetts Biotechnology Council|
Liaison, Scientific & Entrepreneurial Initiatives; Director, Innovation Services,
Lucie has over ten years of experience in conducting biomedical research. She trained in Rennes, France, at the National Center for Research (CNRS) and the National Institute of Health and Medical Research (INSERM). After graduating with her Ph.D., Lucie moved to the US to complete a post-doctoral fellowship at the Massachusetts General Hospital and Shriners Hospital (joint appointment) in Boston, Massachusetts. Committed to foster alliances between Academia and Industry, to facilitate the transfer of technology for the benefit of patients, Lucie joined the largest trade association for the life Sciences, MassBio in 2017 and is Director Innovation Services. Within MassBio, in the Innovation Services team, Lucie created and now leads the Academic outreach and Engagement initiatives. Her mission is to leverage MassBio’s community of members and experts with the goal to facilitate company creation and strategic alliances within academic institutions. Over the last two years, Lucie has built several working groups convening leaders from academia and industry, as well as mentoring programs for academic scientists and joined several advisory boards to foster entrepreneurship beyond the Boston region.
|Gabriel Rocklin||Northwestern University|
Assistant Professor, Pharmacology
Gabriel Rocklin did his Ph.D. research at the University of California, San Francisco,
supervised by Brian Shoichet and Ken Dill. As a postdoctoral fellow with David Baker at the
University of Washington, he pioneered the use of large-scale protein design
to understand protein biophysics. In 2019 he started his independent lab in the Department of Pharmacology and Center for Synthetic Biology at Northwestern University. There, his group develops high-throughput methods to understand protein biophysics and to design new protein therapeutics.
|Eben Rosenthal||Stanford University|
Professor, Cancer Center Medical Director, Otolaryngology
Eben L. Rosenthal is a surgeon-scientist who serves as the John and Ann Doerr Medical Director of the Stanford Cancer Center. He is a Professor of Otolaryngology and Radiology (courtesy) and is clinically active as an oncologic and microvascular reconstructive surgeon. Dr. Rosenthal conducts early phase clinical trials for diagnostic and therapeutic agents for the treatment of solid tumors. He is part of a multidisciplinary team of clinicians and basic scientists that perform preclinical studies, nonhuman primate IND-enabling studies, and first-in-human clinical trials. The lab also focuses on molecular imaging of fluorescently labeled therapeutic antibodies to measure cellular delivery of therapies to tumors and adjacent tissues. Ongoing clinical trials include brain, lung, pancreas, skin and head and neck tumors.
|Valeria Runza, PhD||Roche Diagnostics GmbH|
Head, Functional Characterization, Large Molecule Research, Pharma and Early Development (pRED)
Dr. Runza holds a PhD in Genetics/Immunology and has 10+ years of experience in drug development at Roche. She currently leads the Functional Characterization Department of the Large Molecule Research organization, in charge of developing and implementing the bioassay strategies for all biologics. In previous years, she led several research projects for Cancer Immunology.
|Brandon Ruotolo, PhD||University of Michigan|
Brandon T. Ruotolo is currently a Professor in the Department of Chemistry, University of Michigan. He earned his B.S. in Chemistry from Saint Louis University in 1999. Brandon then received his Ph.D. from Texas A&M University in 2004 under the direction of David H. Russell. He did his post-doctoral work at the University of Cambridge with Dame Carol V. Robinson, and was awarded the first ever Waters Research Fellowship in 2008. Brandon moved to the University of Michigan in 2009, where he began his independent career. The Ruotolo research group at the University of Michigan seeks to enable breakthroughs in structural biology and drug discovery by leveraging the potential of ion mobility-mass spectrometry (IM-MS) for the comprehensive, 3D structural analysis of the proteome. To this end, Ruotolo and his team have studied the role of solvation on biomolecular structure, introduced collision induced unfolding (CIU) - a new fingerprinting technology capable of detecting the structural state of protein-ligand complexes and biotherapeutics, developed software packages for the enhanced interpretation and throughput of IM-MS and CIU data, and investigated the structural consequences of small molecule drug-like compounds on amyloid-related peptides. Ruotolo’s work has resulted in ca. 120 peer-reviewed publications, and many awards, including the Eli Lilly Award in Analytical Chemistry, the NSF CAREER award, the ASMS Research Award, the Protein Science Young Investigator Award, and the Agilent Thought Leader Award.
|Bonnie Rup, PhD||Bonnie Rup Consulting LLC|
Bonita Rup is a biopharmaceutical development consultant, providing expert advice on bioanalysis, immunogenicity risk assessment, and related regulatory strategy aspects of biopharmaceutical development. Previously she was Research Fellow and lead for the Immunogenicity Discipline at Pfizer, Assistant Vice President of Protein Bioanalytics in Wyeth, and held various positions directing development and application of immuno-ligand binding assay technologies for PK, immunogenicity and protein impurity analysis, and other aspects of biopharmaceutical development. During her career, she has been involved in multiple regulatory filings during preclinical, clinical development and marketing approval of biopharmaceutical products. She has been a member of AAPS, EIP, European IMI ABIRISK consortium, and Biosafe; with these organizations, she has been a co-author for multiple publications related to monitoring immunogenicity and bioanalysis of therapeutic proteins. Bonnie received her B.S. from University of Massachusetts, Amherst, Ph.D. from University of Texas, Austin, and conducted postdoctoral research at Duke University and University of Rochester, NY.
|Richard Rustandi, PhD||Merck & Co Inc|
I am a principal scientist in Vaccine Analytical Research Development at Merck Co. I have been in the company for 18 years and have 6 years experiences in working with various therapeutic protein programs. I was responsible in assay developments, CRO transfer, and validation including CMC. And I have been working my other 12 years in vaccine analytical area with similar roles, assay development, validation, and transfer to manufacture plus characterization for BLA. In addition, I have managed biochemistry analytical group for both TP and Vaccine to support fermentation, purification, and formulation areas. This has led me to get involved in establishing several new CE-based technologies to increase efficiency. I hold BS degree from University of Hawaii at Manoa, MS and a Ph.D. in Biophysical Chemistry from the University of Chicago specialized in magnetic resonance (EPR, NMR). I had my postdoctoral experiences at University of Zurich and Harvard Medical School. My current professional associations include committee member in CE Pharm, the American Chemical Society and EPR society, Associate Director in CASSS organization, Distinguished member of Advisory Board at Industrial Pharmaceutical Science at College of Pharmacy in Ewha Womans University.
|Wendy Sandoval||Genentech Inc|
Senior Scientific Researcher
Wendy is a principal scientist at Genentech. She leads the Translational Mass Spectrometry group within the research organization. Her group focuses on mass spectrometry-based strategies to help elucidate protein structure and function. She has a particular interest in native mass spectrometry and it's evolving role in the biopharmaceutical industry. During her more than twenty years at Genentech Wendy has co-authored 70 papers and edited two books, and is happy that she continue to learn new things every day.
|Brian Santich||Memorial Sloan Kettering Cancer Center|
Brian was raised in northern California and got his bachelors degree in immunology at the University of California, Berkeley. Following this, he worked for two years as an IRTA postbac in the laboratory of Dr. Anthony Fauci, under the mentorship of Dr. Susan Moir, studying B-cell dysfunction in HIV and other primary immunodeficiencies. Brian received his PhD from the Louis V. Gerstner Jr. Sloan Kettering Graduate School of Biomedical Sciences under the co-mentorship of Drs. Morgan Huse and Nai-Kong Cheung. His thesis work focused on the structure-function relationship of different T-cell bispecific antibody designs. He now works as a research fellow at Memorial Sloan Kettering Cancer Center, primarily studying T-cell bispecific antibodies and pre-targeted radioimmunotherapy strategies.
|Sumona Sarkar, PhD||National Institute of Standards and Technology|
Biomedical Engineer, Biosystems & Biomaterials Division, Biomaterials Group
Dr. Sumona Sarkar is a biomedical engineer in the Biosystems and Biomaterials Division at the National Institute of Standards and Technology. Dr. Sarkar conducts research in the area of measurement assurance to address analytical challenges in cell therapy and regenerative medicine. She is currently serving as an US expert in the Analytical Methods working group of ISO/TC 276: Biotechnology and has been contributing to the development of standards for cell counting and cell characterization.
|Aaron Sato, PhD||Twist Bioscience|
Aaron is CSO of the Biopharma Vertical at Twist Bioscience. Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics for its clients. He also oversaw all discovery research functions both as Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma, Inc. He also held director level positions at both Oncomed and Dyax Corp.
|Philipp Scherer||University of Texas Dallas|
Professor & Chair, Internal Medicine & Cell Biology
Philipp Scherer is Professor and Director of the Touchstone Diabetes Center at the University of Texas Southwestern Medical Center in Dallas. He received his Ph.D. degree from the University of Basel, Switzerland, followed by post-doctoral training the Whitehead Institute at MIT in Cambridge. In 1997, he joined the faculty of the Albert Einstein College of Medicine where he was a Professor for Cell Biology and Medicine. Throughout his career, he has maintained an interest in processes related to cellular and systemic energy homeostasis. He identified adiponectin, one of the first secretory factors to be described that almost exclusively originate in adipose tissue and which is currently widely studied by many different research groups.
Current efforts in his laboratory are focused on the identification and physiological characterization of novel proteins that serve as potential links between the adipocyte, liver, the pancreatic beta cell and the processes of whole body energy homeostasis, inflammation, cancer and cardiovascular disease.
Scherer has been on the faculty of UT Southwestern Medical Center since 2007 as a member of the Department of Internal Medicine. He holds the Touchstone Distinguished Chair in Diabetes Research and is a member of the Simmons Comprehensive Cancer Center. He was awarded the 2015 Banting Medal for Scientific Achievement from the American Diabetes Association, the 2017 European Association for the Study of Diabetes (EASD) / Novo Nordisk Foundation Diabetes Prize for Excellence and the 2018 Manpei Suzuki Prize in Japan.
|Siew Schleyer||CytomX Therapeutics Inc|
Director, Oncology Research
Siew Schleyer is currently Director of Oncology Research at CytomX Therapeutics. Prior to joining CytomX, she led biotherapeutics research programs in Oncology at Novartis, where she oversaw large molecule programs from early stage research through entry into the clinic. In addition, she worked at Chiron, identifying and validating novel oncology targets, and has authored publications and patents in the field of oncology. Siew obtained her Ph.D. in Immunology at Harvard.
|Dina Schneider||Lentigen Technology Inc|
Associate Director Translational Research
Dina Schneider, Ph.D., is a scientist and an inventor with over-15 years of experience in academia and industry. Dr. Schneider earned her Ph.D. from Michigan State University, and completed her postdoctoral training at the University of Michigan. Her academic career spanned diverse areas of interest, including cellular and molecular immunology, immunotoxicology, inflammation, and molecular biology. In 2011, Dr. Schneider transitioned to industry, where she contributed to numerous projects in synthetic immunology, immunotherapy, and chimeric antigen receptor (CAR) T cell-based therapy. Dr. Schneider leads the Translational Research group at Lentigen Technology, Inc., a Miltenyi Biotec Company, in Gaithersburg, MD. Her group is focused on pre-clinical development of novel CAR-based therapies targeting hematologic malignancies as well as solid tumors, and on the implementation of CliniMACS Prodigy® clinical platform for preparation of cell-based therapeutics. Her recent work includes the development of novel CAR therapies, three of which are now in clinical trials.
|Timothy Schofield||CMC Sciences, LLC|
Owner and Consultant
Tim Schofield is the Owner & Consultant at CMC Sciences, LLC. Prior to starting his own consulting business Tim worked at: GSK as a Senior Advisor in Global Vaccines Technical R&D, and previously a Director in US Regulatory Affairs; MedImmune as a Senior Fellow in Analytical Biotechnology; Arlenda as US Managing Director and Head of Nonclinical Statistics; and Merck Research Laboratories heading the Nonclinical Statistics department. Tim received a Bachelor of Science degree in Mathematics from Lafayette College, and a Master of Arts degree in Statistics and Operations Research in 1976 from the Wharton School of the University of Pennsylvania. Tim is a member of the USP Statistics Expert Committee and has participated in industry initiatives related to Quality by Design, analytical method development and validation, stability and specifications. He is the Chairman of the IABS Publications Committee and a Guest Researcher at NIST.
|Taylor Schreiber||Shattuck Labs Inc|
Taylor co-founded Shattuck Labs and currently serves as Chief Scientific Officer and a member of the Board of Directors. Taylor is the lead inventor of Shattuck’s ARC technology platform. Prior to Shattuck, Taylor served as Chief Scientific Officer of Heat Biologics, Inc. where he was a co-inventor of significant elements of Heat's ImPACT and ComPACT technology platforms. He was also the co-inventor of TNFRSF25 agonist technology developed by Pelican Therapeutics, where he served as Chairman of the Scientific Advisory Board.
|Stefan Seeber, PhD||Roche Innovation Center Penzberg|
Senior Principal Scientist, Cell Line & Molecule Development
Stefan is senior principal scientist and project leader in pRED (Roche Pharma Research and Early Development). He has been active in antibody and cell line development since 1997. In this function he discovered several therapeutic antibodies through all phases from the beginning until entry into human. This included standard antibodies and novel complex format antibodies. In previous positions at Boehringer Mannheim GmbH he worked in oncology projects, developed non-viral and viral vectors for gene therapy programs and tools for molecular biology. Dr. Seeber received his Ph.D. in Biology from the Eberhard Karls University in Tuebingen, Germany. Recently he setup a gene therapy program to develop CMC for AAV-production at Roche, following exactly the session strategy “Transitioning from Therapeutic Proteins to Cell and Gene Therapies”.
|Aude Segaliny, PhD||Amberstone Biosciences|
Group Leader, Assay Biology & Scientific Liaison, Assay Biology,
Dr. Segaliny is a founding scientist of Amberstone Biosciences. She currently serves as the Head of Assay Biology and Scientific Liaison at Amberstone, where she spearheaded the efforts in developing cutting-edge microfluidic-based approaches to enable the discovery of transformative immunotherapeutics. She has 10+ years of experience in cancer biology/immunology.
|Alessandro Sette||La Jolla Institute for Allergy & Immunology|
Professor & Center Head
Dr. Alessandro Sette has devoted more than 30 years of study towards understanding the immune response, measuring immune activity, and developing disease intervention strategies against cancer, autoimmunity, allergy, and infectious diseases. The laboratory is defining in chemical terms the specific structures (epitopes) that the immune system recognizes and uses this knowledge to measure and understand immune responses.
|Khalid Shah||Brigham & Womens Hospital|
Associate Professor of Neurosurgery & Director, Center for Stem Cell Therapeutics & Imaging
No bio available
|Dhavalkumar Shah, PhD||SUNY Buffalo|
Associate Professor, Pharmaceutical Sciences
Prof. Dhaval K. Shah is an Associate Professor of Pharmaceutical Sciences at the State University of New York at Buffalo. Prior to becoming the faculty Prof. Shah served as a Principle Scientist in the ‘Translational Research-Modeling & Simulation’ group at Pfizer Inc. His research focuses on understanding the determinants for the absorption, distribution, metabolism, and elimination (ADME) of protein therapeutics. His lab uses the principles of Pharmacokinetics-Pharmacodynamics (PK-PD) Modeling & Simulation to support the discovery, clinical translation, and late phase development of novel biologics like engineered antibodies, multi-specific proteins, immuno-oncology agents, engineered T cells, and antibody-drug conjugates. He has developed several pioneering systems PK/PD models for ADCs, and continue to develop mechanism models to understand and improve pharmacological behavior of ADCs.
|Susan Sharfstein, PhD||SUNY Polytechnic Institute|
Susan Sharfstein is a Professor of Nanobioscience at SUNY Polytechnic Institute in Albany, New York. Professor Sharfstein received her B.S. in chemical engineering with honors from Caltech in 1987 and her Ph.D. in chemical engineering from UC Berkeley in 1993, receiving graduate fellowships from the university and the National Science Foundation. She received a National Institutes of Health Individual Research Service Award to pursue postdoctoral studies, initially at UC Berkeley and subsequently at the UCLA Medical School. Dr. Sharfstein joined the faculty at the University of Toledo in Bioengineering in 1996. In 2000, she received a National Science Foundation POWRE award to study glycobiology at the New York State Department of Health Wadsworth Laboratories. In 2001, she joined the Department of Chemical and Biological Engineering at Rensselaer Polytechnic Institute, and in 2007, she received a dual appointment in Biology. In 2010, she joined the faculty at SUNY Polytechnic Institute, Colleges of Nanoscale Science and Engineering. Professor Sharfstein received an NSF CAREER grant in 2000 for her work on hyperosmotic stress responses of hybridoma cells and the School of Engineering Education Excellence Award and the Class of 1951 Outstanding Teaching Award in 2007. Professor Sharfstein’s research interests include mammalian and microbial cell bioprocessing, control of protein glycosylation, metabolic engineering, biosensing, and development of systems for high-throughput screening of nucleic acids and small molecules. Professor Sharfstein serves as the subject editor for biotechnology for the Elsevier Major Reference Work Life Science Module. She is the author of over 60 papers and book chapters in the fields of biotechnology and bioprocessing. She was a 2017-18 recipient of a Fulbright Global Scholar award and spent her sabbatical at Dublin City University, in Dublin, Ireland and University of Queensland in Brisbane, Australia performing proteomic analysis of Chinese hamster ovary cells and studying bispecific antibodies.
|Eric Shusta, PhD||University of Wisconsin Madison|
Professor, Chemical & Biological Engineering
Dr. Shusta received his Ph.D. in 1999 from the University of Illinois where he studied the production and engineering of antibodies and T-cell receptors using yeast. He followed this with postdoctoral training at the University of California-Los Angeles where he helped pioneer molecular level analyses of the blood-brain barrier. Currently, Dr. Shusta is the Howard Curler Distinguished Professor in the Department of Chemical and Biological Engineering at the University of Wisconsin. His research focuses on the development of molecular and cellular engineering tools that can help gain a better understanding of blood-brain barrier transport and function. He has been recognized by an NSF Career award, the American Chemical Society BIOT division young investigator award, among others, and was recently elected fellow in the American Institute for Medical and Biological Engineering.
|Rana Sidhu, PhD||UCB Inc|
Group Leader Protein Expressions, New Medicines
I did my graduate work at the University of Manitoba in Canada followed by Post-Doctoral Fellowship at the University of Michigan. I worked at Cayman Chemical for 7 years as the Manager for the Protein Core Group. I then moved to Massachusetts to join Beryllium Discovery just after their acquisition by UCB but before the integration. Currently, I am the Protein Expression Lead at UCB Boston. The team expresses proteins in prokaryotic (primarily E. coli) and eukaryotic (insect and mammalian) expression systems.
|Cornelis Sier||Leiden University Medical Center|
Senior Researcher, Image Guided Surgery
Kees (short for Cornelis) is a molecular biologist especially focused on cell-cell interactions in cancer. He studied molecular biology in Amsterdam (NL) and obtained his PhD in 1993 at the Leiden University Medical Center, investigating the role of proteinases in cancer. After a post-doc in Leiden, he continued his work at the Università Vita Saluta San Raffaele in Milan (IT). In his Italian period, he visited the Mario Negri Institute for Pharmacological Research in Milan (IT) and the Finsen Laboratory, a basic cancer research unit in Copenhagen (DK). He returned to Leiden performing cancer-related research projects in the departments of Pathology, Gastroenterology, and Surgery. In 2010, Kees joined the Image-guided Oncologic Surgery group (Head, dr. Alexander Vahrmeijer) within the department of Surgery. His main focus is the evaluation of tumor markers as target for image-guided surgery and the subsequent development of tracers against selected candidates.
|Mike Singer||FDA CBER|
Medical Officer, Clinical Evaluation & Pharmacology, Center for Biologics Evaluation & Research
No bio available
|Anupam Singhal, PhD||Berkeley Lights Inc|
Anupam Singhal earned his PhD from the University of British Columbia and has over 15 years of experience in nanotechnology and microfluidics at UBC, the University of Toronto and Stanford University. His work has been cited over 600 times and resulted in several patents for molecular disease diagnosis, antibody discovery, and development of production cell-lines for biologics . At Berkeley Lights, Anupam leads the development of next-generation platforms for the discovery and development of antibody therapeutics.
|Dimitris Skokos, PhD||Regeneron Pharmaceuticals Inc|
Director, Immune & Inflammatory Diseases
Dimitris Skokos is a Director in the Immunity and Inflammation department at Regeneron Pharmaceuticals as well as an adjunct faculty Professor at Rockefeller University. He was born and raised in Athens, Greece. In 1998, he double majored receiving degrees in BioMedical Science and Biotechnology, from Ecole Superior in Paris and in Cellular Biology and Physiology from the University of Paris, with High Honors. After earning his Master’s and PhD in Molecular Immunology from Pasteur Institute, he joined the laboratories of Ralph Steinman (Nobel laureate, 2011) and Michel Nussenzweig at Rockefeller University, studying the role of tolerance and immunity in inflammation. In 2008, he joined Regeneron Pharmaceuticals, Inc., where he and his team are leading Regeneron’s efforts in cancer immunotherapy. Dimitris holds more than 10 patents and 25 publications and was part of the team that developed the recently FDA approved treatment for metastatic cutaneous squamous cell carcinoma, Libtayo. He has had the honor to work with esteem scientists, George D. Yancopoulos and Roy P. Vagelos.
|Eric Smith, PhD||Regeneron Pharmaceuticals Inc|
Senior Director Bispecifics
Dr. Eric Smith received his PhD in Microbiology and Immunology from Duke University in 1997. Following a postdoctoral fellowship at NYU he joined Regeneron in 2002 as a member of the Antibody and Trap Technologies group, where he worked on cytokine traps and related molecules. In 2008, he was a founding member of the Bispecific Antibodies team and is currently the Sr. Director of Bispecifics at Regeneron.
|Ernest Smith, PhD||Vaccinex Inc|
CSO & Senior Vice President Research
No bio available
|An Song||Immune Onc Therapeutics|
Chief Scientific Officer
An Song, Ph.D, is Senior Vice President of Development Sciences at Immune-Onc Therapeutics, Inc., accountable for translational development of Immune-Onc’s portfolio, including preclinical PKPD and toxicology evaluation, clinical pharmacology, bioanalytical and biomarker/diagnostic development and certain analytical aspects of technical development. Prior to Immune-Onc, An was a Senior Director in BioAnalytical Sciences at Genentech, where she led the Assay Development and Technology group for the company’s large molecule portfolio globally. During her 16-year tenure at Genentech, An contributed to, and oversaw 40+ IND/CTA and BLA/MAA regulatory filings for products including Rituxan@, Avastin®, Herceptin®, Lucentis ®, Kadcyla®, and Tecentriq®. Additionally, she played a significant role for the development and approval of Ocrevus®.
An holds a B.S. in Biochemistry from Nanjing University in China. She received her PhD. in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in immunology at Stanford University. Upon completion of postdoctoral work in T-cell activation she joined Stanford as a Research Assistant Professor and as faculty of the Immunology Program. An has published a number of original manuscripts, review articles and book chapters, as well as contributed to several industry white papers on immunogenicity and antibody Fc effector function evaluation. She is an active member of American Association of Pharmaceutical Scientist (AAPS), having served as an executive member of the Biotech Section and the chair of Therapeutic Product Immunogenicity (TPI) Focus Group/Community.
Peggy Sotiropoulou joined Celyad in 2017. As Director of the R&D department, she leads a broad-ranging internal research program that aims to develop new strategies in CAR T cell design to target haematological and solid malignancies. Prior to Celyad, Peggy spent 17 years in Academic research in oncology and immunooncology. Before moving to industry, Peggy was associate Professor in the Université Libre de Bruxelles, in Brussels, Belgium, leading research in fundamental oncology and published landmark papers in top tier scientific journals. The aim of Peggy in Celyad is to translate cutting-edge research and innovation into actual treatments for patients.
|Colby Souders, PhD||Abveris|
After his PhD in Cell and Molecular Biology from Texas A&M, Colby joined MassBiologics. There, he led programs to discover and advance mAbs for the prevention, treatment or diagnosis of infectious and endogenous diseases. He later joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. Colby joined Abveris Antibody as Chief Scientific Officer to usher in new antibody discovery tools and build a premium discovery engine.
|Carole Sourbier, PhD||US FDA|
Principal Investigator, Office of Biotechnology Products
No bio available
|Jamie Spangler||Johns Hopkins University|
Assistant Professor, Biomedical Engineering
Dr. Jamie Spangler earned a Bachelor of Science degree in Biomedical Engineering at Johns Hopkins University and went on to complete a PhD in Biological Engineering at MIT under the supervision of Professor K. Dane Wittrup. She conducted postdoctoral training in Professor K. Christopher Garcia’s lab at Stanford University School of Medicine, and then launched her independent research group at Johns Hopkins University in July 2017, jointly between the departments of Biomedical Engineering and Chemical & Biomolecular Engineering. Dr. Spangler’s lab, located in the Translational Tissue Engineering Center at the School of Medicine, applies structural and mechanistic insights to re-engineer existing proteins and design new proteins that therapeutically modulate the immune response. In particular, her group is interested in engineering immune molecules such as antibodies, cytokines, and growth factors for targeted treatment of diseases such as cancer, infectious diseases, and autoimmune disorders. Dr. Spangler’s work has been recognized with honors including a National Defense Science and Engineering Graduate Fellowship, a Leukemia & Lymphoma Society Career Development Fellowship, a V Foundation Scholar award, and a Maryland Stem Cell Research Fund Discovery award.
|Philipp Spycher, PhD||Araris Biotech AG|
Philipp completed his undergraduate studies at the University of Basel (Switzerland) in Nanoscience, graduate studies at ETH Zurich (Switzerland) in Biomedical Engineering and PhD studies in materials and protein engineering at ETH Zurich. Three years post-doc at Prof. Roger Schibli’s lab at PSI Villigen (Switzerland) focused on antibody-drug conjugates followed by being a PSI Founder Fellow for two years at PSI Villigen that resulted in the incorporation of Araris Biotech AG in January 2019 and since June 2019 CEO of Araris.
|Jean Stanton||Johnson & Johnson Pharmaceutical R&D|
Director, CAR T Site Liaison
Jean joined Johnson and Johnson in 2008 after more than 20 years in the health care industry, at a university based medical institution, developing cell-based therapies. During that time, she was responsible for leading the integration of cell and gene therapy regulations into J&J’s internal quality standards. She developed internal training programs to educate organizations within the Pharmaceutical and Medical Device Sectors of J&J. She also played a key role in the development of J&J’s compliance strategies relating to cell-based products. Jean’s responsibilities included; the deployment and maintenance of the R&D compliance program for all GMP aspects within J&J’s Pharmaceutical Sector and the development of the quality and compliance strategies to support all new platforms that are in-licensed or developed within the Sector.
More recently, Jean assumed a new role in Apheresis Operations, supporting cell collections used in CAR-T manufacturing and leading internal efforts to build organizational infrastructure in support these novel products.
|Clifford Steer||University Of Minnesota Twin Cities|
Professor Medicine & Genetics & Associate Dean, Cell Biology & Developmentelopment
No bio available
|Samuel Sternberg, PhD||Columbia University|
Assistant Professor, Biochemistry & Molecular Biophysics
Samuel Sternberg, PhD, received his B.A. from Columbia University in 2007, graduating summa cum laude, and his Ph.D. in Chemistry from the University of California, Berkeley in 2014. After serving as Group Leader of Technology Development at Caribou Biosciences, Inc., he moved back to Columbia University, where he runs a research laboratory and is an assistant professor in the Department of Biochemistry and Molecular Biophysics. Sam's research focuses on RNA-guided bacterial immune systems (CRISPR-Cas) and on the development of these systems for genome engineering. In addition to publishing his work in leading scientific journals, he recently co-authored a popular science trade book together with Jennifer Doudna, entitled A Crack in Creation, about the discovery, development, and applications of gene-editing technology.
|Jan Steyaert, PhD||Vrije University Brussels|
Director & Professor, Structural Biology Brussels Lab
The Steyaert lab pioneered the use of nanobodies for chaperone-assisted X-ray crystallography (www.steyaertlab.eu), aiming at the highest hanging fruits of structural biology including membrane proteins, amyloidogenic proteins, and now also (transient) multiprotein complexes. The elucidation of the first GPCR structures in the agonist-bound active state demonstrate the power of Nanobodies to stabilize G protein coupled receptor conformational states including transmembrane signalling complexes. Recent work focusses on exploiting the conformational complexity of therapeutic targets for Nanobody-enabled drug discovery and on the design of novel antibody formats for applications in single particle cryo-EM.
|Gerald Striedner, PhD||University of Natural Resources & Life Sciences|
Associate Professor at the Department of Biotechnology (BOKU), head of the working group microbial fermentation and principal investigator in the Austrian Center of Industrial Biotechnology (ACIB). The working group has established an integrated systems approach for bioprocess development and is focused on the implementation of PAT and QbD concepts in bioprocessing and rational host cell design. CHO, E. coli, insect cells and vero cell lines are used as expression systems for production of a representative set of biopharmaceuticals (mABs, Fabs, scFvs, VLPs, viruses, DNA.
|Julie Linhui Su||Bristol Myers Squibb Co|
Senior Research Investigator II
Julie received her bachelor’s degree in chemistry with concentration in biochemistry from Duke University. She did her graduate work with Anna Marie Pyle at Columbia University, focusing on the folding of large catalytic RNAs. She then moved to Boston and carried out postdoctoral work in Susan Lindquist’s lab at Whitehead Institute, using yeast as a model for characterizing the disruption of cellular pathways caused by misfolding of alpha synuclein. She joined Bristol Myers Squibb in 2009 and works in discovery, utilizing in vitro selection methods to identify biologic leads for therapeutic targets.
|Traian Sulea||Natl Research Council Canada|
Principal Research Officer, Human Health Therapeutics
Dr. Traian Sulea is a Principal Research Officer who joined the National Research Council Canada as a post-doctoral fellow in 1995. He is also Adjunct Professor at the Institute of Parasitology of McGill University since 2012. Dr. Sulea has broad expertise in applying computational approaches to the discovery and optimization of bioactive small-molecules and biologics. He has contributed to the development of computational methods for biomolecular applications, focusing on continuum solvation models and binding-affinity scoring functions. He has applied structural modeling for bioengineering of growth-factor traps and selective tumor targeting, as well as antibody humanization, conjugation, affinity maturation, de novo design, and developability. Dr. Sulea has authored 95 scientific articles and book chapters and is an inventor on 29 patents issued or pending.
|Magdalena Tary-Lehmann, MD, PhD||Cellular Technology Ltd|
Dr. Magdalena Tary-Lehmann is Co-Founding Scientist and CSO for Cellular Technology Limited (CTL). Dr. Tary-Lehmann received her MD and PhD, both from the University of Tübingen, Germany. Her postdoctoral training in Immunology was at the University of California, Los Angeles. She moved thereafter to Case Western Reserve University, where she was awarded tenure and appointed as Associate Professor in the Department of Pathology. As Chief Scientific Officer for CTL she oversees the performance of immunology assays in CTL’s GCP, GLP- and CLIA compliant contract laboratory for various pharmaceutical and biotechnology clients.
|Sean Taylor||GenScript USA Inc.|
Field Application Scientist Manager, CPBU
Sean is currently working at GenScript USA Inc as Manager of Field Application Scientist. He has over sixteen years of research, scientific writing and collaborative experience with the life scientists, and over eleven years of experience in education in the life science community in the best practices for experimental design and data analysis in common research techniques and lab equipment. Sean holds a Ph.D degree and a Masters of Business Administration degree from McGill University, Montreal, PQ.
|Raymond Tesi||INmuneBio Inc|
CEO & CMO
After an academic career as a transplant surgeon, RJ Tesi joined industry to develop novel therapies to manipulate the immune system; first focusing on immunosuppression and autoimmunity within the adaptive immune system and more recently on the innate immune system in cancer and neurodegenerative diseases. Dr. Tesi is the CEO and CMO of INmune Bio, a NASDAQ company (INMB).
|Peter Tessier, PhD||University of Michigan|
Albert M Mattocks Professor, Pharmaceutical Sciences & Chemical Engineering
Peter Tessier is the Albert M. Mattocks (Endowed) Professor in the Departments of Chemical Engineering, Pharmaceutical Sciences and Biomedical Engineering, and a member of the Biointerfaces Institute at the University of Michigan in Ann Arbor, MI. He received his Ph.D. in Chemical Engineering from the University of Delaware (2003, NASA Graduate Fellow) and performed his postdoctoral studies at the Whitehead Institute for Biomedical Research at MIT (2003-2007, American Cancer Society Fellow). Tessier started his independent career as an assistant professor in the Department of Chemical & Biological Engineering at Rensselaer Polytechnic Institute in 2007, and he was an endowed full professor at Rensselaer prior to moving to the University of Michigan in 2017. Tessier’s research focuses on designing, optimizing, characterizing and formulating a class of large therapeutic proteins (antibodies) that hold great potential for detecting and treating human disorders ranging from cancer to Alzheimer’s disease. He has received a number of awards and fellowships in recognition of his pioneering work: Pew Scholar Award in Biomedical Sciences (2010-2014), Humboldt Fellowship for Experienced Researchers (2014-2015), Young Scientist Award from the World Economic Forum (2014), Young Investigator Award from the American Chemical Society (2015) and NSF CAREER Award (2010-2015).
|Thariska Tharmakulasingam||Kuhner Shaker AG|
Specialist, Orbital Bioreactors
No bio available
|Christy Thomson||Amgen Inc|
Christy Thomson received her PhD in Biochemistry from McMaster University where her research focused on protein structure and function. Her post-doctoral research at the University of British Columbia examined the human antibody response to common pathogens such as HCMV and H1N1. Since joining Amgen in 2012, her focus has been biologic discovery. Dr. Thomson is leader of the Antibody Characterization and Discovery Team which brings together diverse expertise and strategies aimed at early identification of B cells specific to target and the development of assays and reagents to differentiate lead antibodies meeting design goals.
|Nels Thorsteinson||Chemical Computing Group|
Scientific Services Manager, Biologics
Nels Thorsteinson is a Scientific Services Manager specializing in biologics applications for CCG. He is responsible for providing scientific support, programming custom applications, instructing at workshops, presenting at conferences, and guiding CCG's 3D biologics applications development. Nels majored in biomedical computing and graduated focusing on bioinformatics and computational chemistry.
|Greg Thurber||University of Michigan|
Assistant Professor, Chemical Engineering & Biomedical Engineering
Greg M. Thurber is an Assistant Professor of Chemical Engineering and Biomedical Engineering at the University of Michigan. His work focuses on applying fundamental biotransport principles to design novel therapeutics and molecular imaging agents. Prof. Thurber received his training in protein therapeutics at MIT under the guidance of Dr. Dane Wittrup. He then completed his in vivo training in molecular imaging in the laboratory of Dr. Ralph Weissleder at Mass General Hospital and Harvard Medical School. Since joining the faculty at Michigan, he has delivered 26 invited talks at major pharmaceutical companies, national and international conferences, and university departmental seminars. Prof. Thurber works with several pharmaceutical companies as a consultant, collaborator, and/or member of their scientific advisory board. He and his students have presented their interdisciplinary work at chemistry, chemical engineering, and pharmaceutical science conferences. Prof. Thurber has authored 39 peer-reviewed journal publications, 3 book chapters, and numerous conference proceedings. He has received several awards including an NIH K01 award and the National Science Foundation CAREER award.
|Renee Tobias||Halo Labs|
After earning her Masters in Cell and Molecular Biology, Renee worked several years in drug discovery research at companies like Tularik (Amgen), Bayer, and Schering-Plough. She eventually left the bench to pursue more customer-facing roles in applications and product management for life science analytical tools. She is passionate about promoting new, innovative solutions to accelerate biopharmaceutical development, and her current role as Director of Marketing at Halo Labs enables her to do just that.
|Anthony Tolcher||NEXT Oncology|
CoFounder & President & CEO, Clinical Research
Dr. Tolcher is CEO and Founder of NEXT OncologyTM, San Antonio, Texas, a newly founded Phase I group that seeks to transform early clinical trials. NEXT Oncology’s mission is to accelerate the next breakthrough medicines for cancer and the vision is to be the most successful and respected Phase I program in oncology research. Dr. Tolcher served as President and Co-Founder of START LLC from 2009- 2018, one of the world’s largest Clinical Phase I and early drug development operations in cancer medicine with 5 locations in San Antonio Texas; Grand Rapids, Michigan; Madrid Spain; and Shanghai China. Dr. Tolcher is a medical oncologist who has over 25 years’ experience in early drug development and clinical trials. He has been involved in many of the initial phase I studies of new agents that subsequently were FDA approved for the treatment of cancer including pembrolizumab (KeytrudaÒ), copanlisib (Aliqopa), trastuzumab emtansine (KadcylaÒ), regorafenib (StivargaÒ), liposomal vincristine (MarqiboÒ), cabazitaxel (JevtanaÒ), carfilzomib (KyprolisÒ), gefitinib (IressaÒ), erlotinib (TarcevaÒ), and eribulin (HalavenÒ). He is currently the principal investigator on 20 phase I clinical studies, is a reviewer for the Journal of Clinical Oncology, Clinical Cancer Research, and Annals of Oncology. He has chaired the Developmental Therapeutics Review Committee for the American Association of Clinical Oncology Annual Scientific Program. He has a member of over 20 Scientific Advisory Boards for both large and small pharmaceutical companies, as well as a member of the Board of Director for 2 biotechnology companies. Dr. Tolcher has over 100 peer-reviewed publications in scientific journals including Nature, Proceedings of the National Academy of Sciences (USA), Journal of Clinical Oncology, and Clinical Cancer Research, as well as an author of nine book chapters.
|Michael Tovey, PhD||Svar Life Sciences|
Managing Director, Research & Development
Michael brings an extensive knowledge and expertise in molecular genetics, signal transduction, and cell engineering and is the inventor of the iLite™ reporter gene technology. Michael is the author of more than 200 articles on cytokines, biotechnology, and immunogenicity.
|Elizabeth Trehu||Jounce Therapeutics Inc|
Elizabeth (Beth) G. Tréhu, M.D, FACP, is Chief Medical Officer of Jounce Therapeutics, a clinical stage immuno-oncology company dedicated to transforming the treatment of cancer by matching the right immunotherapy to the right patient. Dr. Tréhu designed and conducted her first cancer immunotherapy clinical trials in the early 1990s as an assistant professor and translational researcher at Tufts University School of Medicine, where her research focused on reducing the toxicity of high dose interleukin-2. She has held oncology leadership positions in drug development from IND through post-marketing at Millennium Pharmaceuticals, Genzyme Corporation, Infinity Pharmaceuticals, and Promedior, Inc. and joined Jounce in 2015 to build and lead the clinical organization.
|Nathan Trinklein, PhD||TeneoBio Inc|
Dr. Trinklein is the Chief Technology Officer at Teneobio. Teneobio employs a sequence-based approach for antibody discovery that leverages next-generation sequencing and high-throughput functionally assays to develop fully-human multi-specific antibodies. Prior to Teneobio, Dr. Trinklein was co-founder and CEO of SwitchGear Genomics, a venture-backed company that was acquired in 2013. Dr. Trinklein served as the Technical Director of the Stanford ENCODE project and received his PhD from Stanford University. Dr. Trinklein has published over 20 peer-reviewed papers and is an inventor on over 15 patents.
|Jogender Tushir-Singh, PhD||University of Virginia School of Medicine|
Assistant Professor, Biochemistry & Molecular Genetics, UVA Cancer Center
No bio available
|Pablo Umaña, PhD||Roche Innovation Center Zurich|
Head, Cancer Immunotherapy Discovery
Pablo Umaña is Head of Cancer Immunotherapy Discovery. He obtained his PhD in Chemical Engineering and Biology from the California Institute of Technology in 1998 carrying out experimental work at ETH-Zurich. In 2001, he co-founded GlycArt Biotechnology AG in Zurich-Switzerland, a company spinning out of research carried out at the ETH-Zurich and headed its research since the company’s foundation. To date, he continues to lead research at the Roche Innovation Center Zurich as part of the Pharma Research and Early Development (pRED) organization within Roche, after GlycArt was acquired by Hoffmann La Roche AG in 2005. He led the team that discovered and initially developed GAZYVA, a novel Type II CD20 antibody for the treatment of B-cell malignancies. GAZYVA was approved on Nov 1, 2013 by FDA for 1L CLL and is the first ever medicine approved by the FDA under the Breakthrough Therapy regime. He has also led the research for the generation and initial development of Roche-pRED’s tumor-targeted-T-cell bispecific, -immunocytokine and -immunomodulator platforms and drug candidates in the field of cancer immunotherapy.
I got my Bachelor’s in Chemistry and Philosophy at Creighton University in Omaha working in synthetic organic chemistry. I then went to the University of Minnesota, where I received my Ph.D. working under Will Pomerantz developing protein-observed fluorine NMR as a ligand discovery technique. Since then I’ve been working in the high-throughput protein engineering group at AbbVie Bioresearch Center to design, produce, and analyze proteins in high-throughput.
|Bob Bahram Valamehr||Fate Therapeutics Inc|
Chief Developmentelopment Officer
Bob Valamehr is the Chief Development Officer at Fate Therapeutics, overseeing the company’s early development activities including “off-the-shelf” cell therapy products derived from the company’s induced pluripotent stem cell platform. Previously, Dr. Valamehr was the Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.
|Salvatore Valitutti, MD||INSERM Transfert|
Salvatore Valitutti, MD, former full professor of immunology at the University of Toulouse, France is Director of Research at INSERM. He has been working for more than twenty years on T lymphocyte activation by antigenic determinants displayed on antigen presenting cell (APC) surface and has acquired uncommon expertise on in vitro and in tissue study of human primary immune cells. Dr. Valitutti has been member of the Basel Institute for Immunology in Basel, Switzerland where he contributed to the understanding of basic mechanisms of T lymphocyte activation. More recently, in Lausanne (Switzerland) and in Toulouse (France), Dr. Valitutti has contributed to define the structure, dynamics and function of immunological synapses, formed by both helper and cytotoxic T cells. His research team develops, at the INSERM U1043 in Toulouse, a multi-disciplinary research program in which, biologists in collaboration with clinicians, computer scientists and mathematicians, investigate different aspects of the intercellular communication occurring at immunological synapses in human health and disease.
|Daniel Vallera, PhD||University Of Minnesota Twin Cities|
Professor Radiation Oncology, Therapeutic Radiology
Professor of Radiation Oncology and member of the NCI-designated Mesonic Cancer Center, University of Minnesota Director of the Laboratory of Molecular Cancer Therapeutics. Currently, Lion Scholar. PhD from Ohio State University in Immunology and Oncology 1978. Past Leukemia Society and ACS scholar. Over 200 career publications on PubMed. Specialist in the genetic engineering of new anti-cancer drugs designed to use antibodies to selectively target carcinoma and leukemia. Have assembled a drug facility at the U of M that allows cGMP production of biological drugs. Have FDA sponsored 3 drugs and taken these from Bedside to the clinic.
|Thomas Van Blarcom||Allogene Therapeutics|
Senior Director & Head
Tom Van Blarcom received his Ph.D. in Chemical Engineering from The University of Texas at Austin, where he worked on the development and application of cell surface display systems for antibody engineering. Afterwards he joined the Protein Engineering Department at Pfizer’s South San Francisco location where he continued to develop novel technologies for antibody engineering including cell surface display, synthetic antibody library design and library synthesis technologies and applied them to improve the development of therapeutic monoclonal antibodies, bispecific antibodies and CAR T cells. Since then, he has continued his work on CAR T cells by joining Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T cell (AlloCAR TTM) therapies for cancer. At Allogene, Tom oversees all protein engineering activities and contributes to various aspects of CAR T cell design and engineering.
|Johannes Van den Heuvel, PhD||Helmholtz Center for Infection Research|
Research Group Leader, Recombinant Protein Expression
I am a Biochemist and did my PhD in Biotechnology in Amsterdam at the Free University. Since 1990 I developed my career in protein expression and purification, starting at the German Research Institute for Biotechnology (GBF) in Braunschweig Germany investigating gene expression and biochemical engineering. After the renaming of the institute into the Helmholtz Centre for Infection Research (HZI) my research focus changed to integrative structural biology. I am currently Head of the Protein Sample Production Facility (PSPF) at the HZI and Research Group Leader for recombinant protein expression.
|Bas van der Woning||argenx BVBA|
PhD in cell biology. 10 years’ experience in antibody engineering. Was responsible for pre-clinical development of ARGX-115, targeting GARP-TGFβ1, for immuno-oncology, until AbbVie took over for clinical development. Lead scientist TGFβ-related projects and project leader on the ARGX-118 project for severe asthma.
|Rodrigo Vazquez-Lombardi||ETH Zurich|
PostDoc Lab for Systems & Synthetic Immunology, Biosystems Science & Engineering
Dr. Rodrigo Vazquez-Lombardi is a research scientist specializing in therapeutic protein engineering and immunology. As part of his PHRT Postdoctoral Fellowship at ETH Zurich (D-BSSE, Basel), he is currently developing novel tools for use in T cell immunotherapy applications.
|Erik Vernet||Novo Nordisk Research Center|
Director, Protein Engineering, Discovery Biologics
Erik has a background in Biotechnology from the Royal Institute of Technology in Stockholm, Sweden, from where he earned his PhD working on alternative scaffold affinity proteins. This was followed by postdoctoral training on high-throughput protein production and characterisation at the Novo Nordisk Foundation Center for Protein Research in Copenhagen, Denmark. After joining Novo Nordisk A/S in Denmark in 2011, Erik has held various project and line manager positions in protein science, bioinformatics and laboratory informatics. Since 2017 Erik is head of Discovery Biologics at Novo Nordisk Research Center Seattle, WA, responsible for compound generation, analysis and characterization in the discovery pipeline.
|Birgit Viira||Icosagen Cell Factory OU|
Key Account & Technology Officer
No bio available
|Steven Walfish, MBA||USP|
Principal Scientific Liaison
Mr. Walfish is Principal Science & Standards Liaison in the Global Science and Standards Division at United States Pharmacopeia (USP). Prior to this role Mr. Walfish was Principal Statistician at BD in Franklin Lakes, NJ. Steven was President of Statistical Outsourcing Services, a consulting company that provides statistical analysis and training to the FDA regulated industries. His expertise is in statistical methods for assay validation and CMC statistics. Mr. Walfish holds a Bachelors of Arts in Statistics from the University of Buffalo, Masters of Science in Statistics from Rutgers University and an Executive MBA from Boston University.
|Benjamin Walters||Genentech Inc|
I am generally interested in how protein structural dynamics drives biological activity and using this information to make better drugs and more stable formulations. Mass spectrometry has proven to be a terrific tool for many questions related to these aims. Currently, my group focuses on applications MS to enable covalent drug discovery and as projects progress in the research portfolio, we use hydrogen exchange measurements in a variety of ways to enhance structure-based drug design and SAR efforts.
I graduated from North Carolina State University with a B.S. in Biochemistry in 2006 and obtained my Ph.D. in Biochemistry and Molecular Biophysics in 2013 from the University of Pennsylvania. I completed an industrial post-doc at Genentech in 2016 and liked it so much I decided to stay.
|Perry Wang, PhD||FDA CFSAN|
Dr. Perry G. Wang is a chemist in the Office of Regulatory Science, US Food and Drug Administration (US FDA). His interests include analytical method development and validation for drugs and constituents of foods and cosmetic products using advanced instrumentation. His expertise focuses on high throughput drug analysis by LC/MS/MS. His current research focuses on developing analytical methods for constituents in cosmetics and dietary supplements by GC/MS/MS and LC/MS/MS. He received his PhD from Oregon State University and BS from Shandong University.
|Sally Ward, PhD||University of Southampton|
Professor, Molecular Immunology
Sally Ward completed her Ph.D. research in the Department of Biochemistry at Cambridge University in 1985 under the mentorship of Professor David Ellar. From 1988 to 1990, she carried out research on antibody repertoire technology in Sir Greg Winter’s laboratory at the MRC Laboratory of Molecular Biology in Cambridge. In 1990 she joined the University of Texas Southwestern Medical Center, Dallas, as an Assistant Professor. From 2002-2014, she was a Professor in the Department of Immunology at the same institution and in 2004 was appointed to the Paul and Betty Meek-FINA Professorship in Molecular Immunology. Since 2014, she has been a Professor at Texas A&M University Health Science Center, and has recently been appointed as Director of Translational Immunology and Professor of Molecular Immunology at the Centre for Cancer Immunology in Southampton, U.K. In 2010, she was a founding co-organizer of the Gordon Research Conference ‘Antibody Biology and Engineering’. She is a member of the Board of Directors of the Antibody Society and serves on the editorial boards of mAbs and Protein Engineering, Design and Selection. Her interdisciplinary research involves the use of a combination of fluorescence imaging, protein engineering and in vivo studies to develop antibody-based therapeutics to treat cancer and autoimmunity.
|Norihiro Watanabe||Baylor College of Medicine|
PostDoc Associate, Gene Therapy Center
Dr. Watanabe is an Instructor at the Center for Cell and Gene Therapy, Baylor College of Medicine with a long-standing interest in the development of novel immunotherapeutic strategies. His research areas include developing T cell-based approaches for the treatment of both hematological malignancies and solid tumors. Since joining CAGT, he has been focusing on optimizing genetic engineering strategies to maximize the potency of tumor-targeting T cells and developing novel T cell-based therapeutic platforms.
|Louis Weiner||Georgetown University|
Professor & Director, Oncology, Lombardi Comprehensive Cancer Cneter
Dr. Louis Weiner is director of Georgetown Lombardi Comprehensive Cancer Center, one of 49 National Cancer Institute (NCI)-designated comprehensive cancer centers in the United States. He holds the Francis L. and Charlotte G. Gragnani Chair and is professor of oncology and chair of the Department of Oncology at Georgetown University Medical Center. He also serves as the Director of the MedStar Georgetown Cancer Institute, a cancer service line serving patients in the Washington DC and Baltimore metropolitan areas. He is responsible for the operation and development of the cancer center, including its research, clinical, and educational missions. The clinical mission includes leading the MedStar-Georgetown Cancer Network in the metropolitan Washington area. Weiner is known for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies and other modalities of therapy. His current research focuses on identifying and therapeutically exploiting mechanisms employed by malignant cells to combat immune destruction. Prior to joining Georgetown Lombardi as director in 2008, Weiner served as chairman of the medical oncology department and vice president for translational research at Fox Chase Cancer Center in Philadelphia, PA, and also served as professor in the department of medicine at Temple University School of Medicine. He is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research (AACR), and founded the AACR Cancer Immunology Working Group. He has served as chair of the NCI Board of Scientific Counselors for Clinical Sciences and Epidemiology and as a member of the NCI Clinical Trials Advisory Committee (CTAC). He also served on the NCI’s blue ribbon panel working group on immunotherapy for the National Cancer Moonshot Initiative and the Advisory Panel of the National Institutes of Health (NIH) Center for Scientific Research (CSR), which administers NIH research grants. He is recipient of the 2019 AACR Distinguished Public Service Award. Weiner earned his bachelor degree in biology with honors from the University of Pennsylvania and his M.D. from Mount Sinai School of Medicine. After completing his internship, residency, and service as chief medical resident at the University of Vermont’s Medical Center Hospital, he held clinical and research fellowships in hematology and oncology at Tufts University School of Medicine in Boston.
|Gregory Weiss, PhD||University of California Irvine|
Professor, Chemistry & Molecular Biology & Biochemistry
Gregory Weiss is a Professor of Chemical Biology at the University of California, Irvine (UCI). He earned a BS from UC Berkeley and a PhD from Harvard. His undergraduate and graduate research focused on the development of heterocyclic mimics of peptides. Awarded a Ruth Kirschstein National Research Service Award from the NIH, he returned the funding to pursue post-doctoral studies with Dr. Jim Wells, then at Genentech. In 2000, he joined the faculty at UCI where his laboratory focuses on the interface between chemistry and biology, including studies of enzymes, molecular recognition, and bioelectronics. His awards include Outstanding Professor in the School of Physical Sciences at UCI (elected by the graduating students), Beckman Foundation Young Investigator, and election to Fellow of the American Association for the Advancement of Science. He has published around 100 peer-reviewed articles in chemical biology, biophysics, biochemistry, molecular biology, and organic chemistry. He co-founded and was twice elected co-chair of the Global Young Academy, which includes 200 top young scientists from >55 countries. With Dr. David Van Vranken, he co-authored Introduction to Bioorganic Chemistry and Chemical Biology. In 2015, he was awarded the Ig Nobel Prize in Chemistry for leading the team that partially unboiled the egg. He has started two biotech companies and is UCI’s Entrepreneurial Leader of the Year in 2018. He and his wife live in Irvine, California with their three cats.
|James Wells, PhD||University of California San Francisco|
Professor, Pharmaceutical Chemistry
Jim pioneered the engineering of proteins, antibodies, and small molecules that target catalytic, allosteric, and protein-protein interaction sites. He developed technologies including protein phage display, alanine-scanning, engineered proteases for improved hydrolysis, bioconjugations, N-terminomics, disulfide “tethering” (a novel site-directed fragment-based approach for drug discovery), and more recently an industrialized recombinant antibody production pipeline for the proteome and protein-Seq. These lead to important new insights into protease mechanisms, growth factor signaling, hot-spots in protein-protein interfaces, role of caspases in biology, and more recently determining how cell surfaces change in health and disease. His team was integral to several protein products including Somavert for acromegaly, Avastin for cancer, and engineered proteases sold by Pfizer, Genentech and Genencor, respectively. At Sunesis where he was President and CSO his team discovered the LFA-1 antagonist, Lifitegrast, now FDA approved for dry eye disease through SARcode and sold by Shire. He has published over 200 peer-reviewed papers and inventor on more than 60 patents. Dr. Wells received a B.A. degree in biochemistry from the UC Berkeley, a Ph.D. degree in biochemistry from Washington State University with Professor Ralph Yount and completed postdoctoral studies at Stanford University Medical School with Professor George Stark. He joined Genentech in 1982 as a founding member of the Protein Engineering Department, Founded Sunesis Pharmaceuticals in 1998 and joined UCSF in 2005 now as Professor and former Chair of Pharmaceutical Chemistry. In 1999, he was elected member of the National Academy of Sciences, 2015 elected member in the American Association of Arts and Sciences, and 2016 the National Academy of Inventors.
|Megan Wiberg||PPD Inc|
Megan Wiberg’s career spans more than 20 years of using ligand binding assays (LBAs) to detect drug concentrations, anti-drug antibodies (ADAs) and biomarkers. Working for the CRO industry in regulated bioanalysis throughout that time has given her exposure to a wide variety of biologics and approaches across a diverse set of sponsor companies. It has also allowed her to observe the evolution of regulatory requirements for LBAs and ADAs in real time. After several years of performing assays in the laboratory, Megan served many more as a Principal Investigator for assay development, validation, and sample analysis projects. This expanded into various levels of supervisory roles where she had the opportunity to spread her knowledge and experience to others. In her current role as a Manager in the Immunochemistry department at PPD, she oversees a team of more than 60 scientists in support of assay validation and long-term implementation of methods for nonclinical and clinical study support.
|Ian Wilkinson||Absolute Antibody Ltd|
Ian’s background is firmly in the engineering and development of therapeutic antibodies. Having solved the first NMR structure of a human antibody fragment (UCB-Celltech, University of Leicester) Ian oversaw therapeutic research projects covering technology validation, drug discovery and optimization (MedImmune, AstraZeneca) before joining Absolute Antibody at its founding in 2012.
|Yariv Wine, PhD||Tel Aviv University|
Assistant Professor, Molecular Cell Biology & Biotechnology
Dr. Wine graduated from Tel Aviv University in the Department of Molecular Microbiology and Biotechnology at the Faculty of Life Sciences under the supervision of Prof. Amihay Freeman and Prof Felix Frolow, where using structural biology, protein chemistry, computerized modeling and molecular biology tools, he studied various aspects of protein-protein interactions for the design of novel composite materials within the nano-biotechnology field. During his postdoctoral training at the laboratory of Prof. George Georgiou (UT, Austin), Dr. Wine focused on developing a novel approach for the in-depth analysis of the humoral response following vaccine or disease. Following his postdoc training he established his research group at Tel Aviv University. As a group leader, Dr. Wine utilizes his recently developed approach combined with earlier acquired tools to study: i) maternal-infant immunity by profiling the molecular composition, dynamics and attributes of maternal, trans-placental and breastmilk vaccine-specific antibodies; ii) Anti-drug antibodies following treatment with Biologics and ; iii) anti-bacterial antibodies to be used as next generation antibiotics. Collectively, Dr. Wine’s research group aims to address basic immunological questions as well as application-focused research for vaccine evaluation, development and design, immunodiagnostic discovery, and monoclonal antibody engineering.
|K Dane Wittrup, Jr., PhD||Massachusetts Institute of Technology|
CP Dubbs Professor, Chemical Engineering & Bioengineering
Prof. Dane Wittrup attended the University of New Mexico as an undergraduate, graduating Summa Cum Laude with a Bachlor’s in Chemical Engineering in June 1984. Wittrup went on to attend the California Institute of Technology in Pasadena, where he worked with Prof. James Bailey on flow cytometry and segregated modeling of recombinant populations of Saccharomyces cerevisiae. After obtaining his PhD in Chemical Engineering with a minor in Biology in 1988, he spent a brief time working at Amgen before becoming an Assistant Professor of Chemical Engineering at the University of Illinois at Urbana-Champaign in 1989. He moved to the Massachusetts Institute of Technology in September of 1999, where he is now the C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, in addition to working with the Koch Institute as the Associate Director for Engineering.
|Kurt Wüthrich, PhD||ETH Zurich|
Kurt Wüthrich is the Cecil H. and Ida M. Green Professor of Structural Biology at Scripps Research, La Jolla, CA, USA, Professor of Biophysics at the ETH Zürich, Zürich, Switzerland, and Distinguished Senior Professor at the iHuman Institute, ShanghaiTech University, Shanghai, China. For 50 years, Wüthrich groups at the ETH Zürich, at Scripps Research and at the iHuman Institute have used nuclear magnetic resonance spectroscopy (NMR) for research in structural biology. Contributions include the method of protein structure determination with NMR in solution, and the use of the principles of transverse relaxation-optimized spectroscopy (TROSY) for NMR experiments with large supramolecular assemblies. Applications over the years were focused on differentiation in higher organisms, immune suppression and neuropathology. As of April 2019, research using NMR techniques is continued at ShanghaiTech University, with a focus on transmembrane signal transfer by G protein-coupled receptors (GPCRs). At Scripps Research and the ETH Zürich, projects on the general theme “healthcare in the ageing human societies of the 21st century” are pursued, mainly considering the impact of sarcopenia on the human healthspan. Kurt Wüthrich’s achievements have been recognized by the Prix Louis Jeantet de Médecine, the Kyoto Prize in Advanced Technology, the Nobel Prize in Chemistry, and by a number of other awards and honorary degrees.
Senior Scientist, Analytical Developmentelopment
I have been working at Biogen since early 2013, participated in the analytical assay development from both biological and chemical perspectives for protein pharmaceuticals as well as AAV-based gene therapeutics. Prior to the current role, I spent 5 years in industry optimizing nucleic acid-based diagnostic instruments and reagents for contagious and inherited diseases, after obtained my PhD degree in Biological Chemistry at the University of Michigan and completion of postdoctoral training at MIT and Brandeis University in the field of molecular and cell biology.
|Weifeng Xu||Merck Research Labs|
Principal Scientist & Group Leader, PPDM
Weifeng has been in the field of immunogenicity for biologics for about 10 years. He had developed cell-based neutralization Ab assays for multiple key product at BMS including Opdivo and Yervoy. He is an active member in AAPS NAb work group as well as EBA NAb team; he is also co-leading the NAb assay drug tolerance subteam at AAPS. After join Merck at the end of 2018, Weifeng is now leading Cell Assay group within PPDM Regulated Immunogenicity to develop neutralizing assays for both biologics and vaccines.
|Gur Yaari||Bar Ilan University|
Gur Yaari is an Associate Professor in the Faculty of Engineering of Bar Ilan University, Israel. He received his BSc degree in physics and math, MSc in high energy physics, and PhD in interdisciplinary physics, all from HUJI. He was a postdoctoral fellow at Yale University. Yaari joined the faculty of Engineering in 2013. His current research interest focuses on the development of computational and statistical tools to process and analyze high-throughput biological data, with a special spotlight on the adaptive immune system.
|Kun Yang, PhD||Merck|
Associate Principal Scientist, PPDM
Kun Yang, Ph.D. is currently an Associate Principal Scientist at Regulated PK Bioanalysis within the Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPDM) in Merck Research Laboratories. In PPDM BA, Kun is responsible for critical reagents generation and characterization strategy to support regulated preclinical and clinical studies for biologics and vaccines. In addition, he was a technical lead in the development and validation of bioanalytical assays at Merck. Kun has 10 years’ experience at leading pharmaceutical companies and was working on vaccines, small molecule, and biological drugs. Kun was responsible for the development of clinical and manufacturing processes for new therapeutic protein candidates. Kun’s technical expertise includes preclinical and clinical pharmacokinetics pharmacodynamics, absolute quantification of biologics molecules by immunocapture-LC/MS/MS and LBA in biological matrices to support PK for pre-clinical and clinical studies, and ADME. Kun also has extensive experience with bioprocess (from preclinical batch to clinical batch) including cell culture, purification and analytical characterization, process optimization, process characterization, process scale-up, technology transfer, validation, and biomanufacturing. Kun received his Ph.D. in Biochemistry from University of Texas Southwestern Medical Center at Dallas.
|Zhi-Yong Yang, PhD||Sanofi|
Head of Immunomodulation/Immunotherapy, NA Breakthrough Laboratory
No bio available
|Alexei Yeliseev, PhD||NIH NIAAA|
Staff Scientist & Group Leader LMBB, Nuclear Magnetic Resonance
Alexei Yeliseev is a Staff Scientist, head of the protein biochemistry group at the National Institute on Alcoholism and Alcohol Abuse, National Institute of Health. His research focuses on developing technologies for expression, purification, and functional and structural characterization of G protein-coupled receptors. In addition to his research work he serves as a member of editorial board of Protein Expression and Purification.
|Michael Yellin||Celldex Therapeutics Inc|
Vice President Clinical Science
No bio available
|Junming Yie, PhD||Merck Research Laboratories|
Principal Scientist, Cell Based Assays, Biologics AR&D
Dr. Junming Yie is a Principal Scientist in the cell-based assay group of the Biologics Anayltical R&D in process development at Merck & Co.. Having been in the biotech/pharmaceutical industry since 2001, Dr. Yie have spent six years at Pfizer and eight years at Amgen before joining Merck in 2015. Considering himself as expert in metabolic diseases, Dr. Yie spent his first 15 industrial years in the discovery research, mainly focused on the metabolic diseases such as diabetes, obesity, NASH, muscular and cardiovascular diseases. During this period, Dr. Yie have worked on more than a dozen projects and have led a few projects from conceptual ideas to the delivery of clinical candidates. Dr. Yie have led projects for delivering two monoclonal antibodies from two different projects, three small molecule candidates, and has been a key contributor for delivering three recombinant protein candidates into clinical development. Having seen enough discovery research, Dr. Yie moved into the current role in the cell-based assay group of Biologics AR&D, and started to learn the knowledge in bioprocess and CMC. Dr. Yie first worked on a biosimilar program, and developed a functional cell-based assay to replace USP<121> rabbit blood sugar bioidentity assay. He learned to appreciate the rigorous criteria of assay development for GMP and GLP purposes. Later on, Dr. Yie and his team has developed serveral cell-based assays for projects in immuno-oncology, virology and metabolic diseases. Dr. Yie is also leading an analytical effort as analytical project leader for a Phase 3 bioprocess development, and has taken the new challenges to expand his knowledge across CMC realm.
|Travis Young||California Institute for Biomedical Research|
Vice President Biologics
Dr. Young is the Vice President of Biologics at Calibr, a division of Scripps Research, where he was a member of the founding principal investigators. He currently serves as the lead investigator on multiple bench-to-bedside antibody and cellular therapy-based programs. Dr. Young maintains a research group focused in the development of novel therapeutics at the interface between protein engineering and synthetic biology. This research spans multiple disease indications including cancer, autoimmune, metabolic disorders, and infectious disease. His work has been highly awarded and received support from the Wellcome Trust, NIH (National Cancer Institute), Department of Defense, Mesothelioma Research foundation, American Cancer Society, among others, in addition to receiving backing from major pharma groups which supports clinical translation of programs. His work has resulted in numerous publications and patents with ~2000 citations in the past 5 years. He received a BS in biochemistry from Boston College and a PhD in chemical biology from The Scripps Research Institute as an ARCS scholar. At Scripps, his work was foundational for the development of programs in the Calibr pipeline today, including a bispecific antibody for prostate cancer which will enter clinical trials next year. After receiving his PhD, he completed a postdoc at Harvard Medical School with an NIH fellowship, in the department of Biological Chemistry and Molecular Pharmacology.
|Xinchao Yu, PhD||Amgen Inc|
Senior Scientist, ImmunoOncology & Molecular Engineering
Dr. Xinchao Yu is a senior scientist and cryo-EM lab head at Amgen South San Francisco. Xinchao received his Ph.D. in Biophysics from Boston University with comprehensive training in single particle cryo-EM. During his postdoctoral career at the Memorial Sloan-Kettering Cancer Center, he used a combination of X-ray crystallography and cryo-EM to study molecular machineries involved in membrane trafficking processes, as well as honing his expertise in membrane protein expression and purification. With a passion to pursue innovative medicine to help patients, Xinchao joined Amen in 2015 to lead the cryo-EM initiative to set up the cryo-EM infrastructure to support drug discovery. Through extensive cross-functional and cross-sites collaborations, Xinchao and the cryo-EM team have made significant progress to support a number of important research pipelines, including several challenging membrane protein targets.
|Shlomo Zarzhitsky, PhD||Princeton University|
Research Associate, Chemistry
Shlomo Zarzhitsky is a research associate at Princeton University working with Prof. Michael Hecht. His research focuses on the utilization of synthetic proteins in the expression of Difficult-to-Express-Proteins. Shlomo is a biotechnology engineer with extensive experience in the design and characterization of peptides and proteins.
|Ming Zeng||Bristol Myers Squibb Co|
Dr. Ming Zeng is currently working at Bristol Myers Squibb Company leading biologics drug product development analytics teams. Ming received her PhD in Organic/Natural Product Chemistry from Univ of Maryland where her research focus was to develop the first generation of ADCs. She has more than 15 years of extended biologics characterization and method development experience. She was one of the primary authors for Opdivo® and Empliciti® BLA analytical sections.
|Bin Zhang||Northwestern University|
Associate Professor, Medicine & Hematology & Oncology
Dr. Zhang has been trained as a physician and then earned a PhD in Cell Biology in Chinese Academy of Medical Sciences & Peking Union Medical College. Following a CRI postdoctoral fellowship at the University of Chicago, he began his independent career at the University of Texas Health Science Center at San Antonio, as an Assistant Professor of Medicine. Subsequently, Dr. Zhang moved his research laboratory to Northwestern University where he is currently Professor of Medicine, and Microbiology-Immunology, as well as Co-Director of Immune Assessment Core, at the Robert H. Lurie Comprehensive Cancer Center. The Zhang group focuses on integrated translational research program with the goal of designing and developing new immunotherapies and immunologic strategies for cancer treatment together with an interdisciplinary approach to nanomaterials research. His work has directly promoted the initiation of a number of clinical trials. Dr. Zhang has published over 90 scientific papers, many in high-impact journals including Immunity, J Exp Med, Nat Commun, PNAS, and J Clin Invest. He has been serving as Editors of several leading journals including J Immunol and Front Oncol. Dr. Zhang has also served on several NIH study sections and currently is standing member of the National Institutes of Health (NIH) Cancer Immunopathology and Immunotherapy (CII) study section. Dr. Zhang’s research has been continuously funded for more than two decades by NCI, DOD and other federal, state and private funding agencies.
|MeiYun Zhang||Amgen Asia R&D Center|
Principal Scientist, Antibody Discovery
Dr. Mei-Yun Zhang obtained her B.A. in Genetics and M.S. in Biochemistry from China Agricultural University, and Ph.D. in Natural Science from Aachen Technical University, Germany. After a postdoc training in NCI, NIH, she was promoted to Scientist. She was appointed Assistant Professor and served as a Faculty member in the Department of Microbiology, The University of Hong Kong. She then moved on to biotech industry and joined Amgen in 2015 as Principal Scientist, Antibody Discovery Lead at Amgen China R&D Center. She has conducted extensive basic research in cancer and infectious diseases and led biologics drug early discovery throughout her career. She has 56 peer-reviewed publications and holds 7 issued patents or patent applications. Since she joined Amgen, she has been focused on developing innovative technologies for antibody discovery and established camelid single domain antibody platform and antibody phenotypic screening platform at Amgen.
|Zhengjian Zhang||Surrozen Inc|
Senior Scienist, Discovery
No bio available
Principal Scientist & Leader & Section Head, Gene Therapy
Dr Zhao obtained her PhD at Manchester University and gained her postdoctoral experiences at the University of Oxford, CR-UK Cancer Institute and UCL before joining NIBSC in 2001. She has a strong background in gene therapy, virology, molecular biology, cell biology, cancer research and developmental biology. Her research interests lie in vector development based on Retrovirus, Parvovirus and Baculovirus. She has been an active Expert member of EMA/CAT Gene Therapy Working Party, EDQM/OMCL gene therapy group, ICH and ISO Drafting Group, contributing to the development of European and International Guidance on Advance Therapies.
|Xiaomai Zhou||Hangzhou DAC Biotech Co Ltd|
Vice President Biology
Dr. Xiaomai Zhou obtained his Ph.D. Degree from Dr. Lew Cantley’s Lab at Tufts University, and did his postdoctoral research in Dr. Joan Brugge’s Lab at ARIAD Pharmaceuticals. He has worked 12 years on ADC research at ImmunoGen, Inc., and 5 years on exploratory therapeutic antibodies at Boehringer Ingelheim. Dr. Zhou has been the Vice President at Hangzhou DAC Biotech in the past 6 years, leading the company's efforts in molecular and cell biology, antibody engineering and production processes, as well as cell-based ADC functional evaluation. He has been involved in leading a series of new ADC projects with the company’s intellectual properties. The first innovative ADC is in phase I clinical trials, and this presentation will be on the attractive features and promising results of the second ADC drug.
|Yizhou Zhou, PhD||Biogen|
Scientist II, Cell Culture Developmentelopment
Yizhou Zhou is a Scientist in Protein Development of Biogen. She leads vector design, genetic characterization, and multi-omics analysis to support cell line and cell culture process development. She obtained her Ph.D. in Molecular Biology at the University of Michigan, and worked at Genentech before joining Biogen.
|Eugene Zhukovsky, PhD||Biomunex Pharmaceuticals|
Dr. Zhukovsky has over two decades of professional experience in the field of biotherapeutics research and development. He currently applies optimized monospecific and novel bispecific antibody platforms to the development of immunotherapeutics for cancer, with a particular focus on leveraging the biology of immune checkpoint modulators. Currently, Dr. Zhukovsky is the CSO of Biomunex Pharmaceuticals, and he also consults with other biotechnology companies. Previously, he served as the CSO of Affimed Therapeutics; there he was responsible for the advancement of candidate therapeutics from discovery to the clinic, and novel technology development. Prior to that he was a Senior Research Fellow in the Biotherapeutics Department at Boehringer Ingelheim Pharmaceuticals, Inc. leading antibody discovery efforts in the therapeutic areas of inflammatory and cardiovascular diseases. Prior to that Dr. Zhukovsky was an Associate Director at Xencor, Inc. where he led translational research efforts resulting in several therapeutic candidates targeting malignant B cells. One of these therapeutic antibodies is currently undergoing late-stage clinical trials. Dr. Zhukovsky began his professional career employing phage display technology at Neurex Corporation. He then moved to Lynx Therapeutics (now Illumina, Inc.) to work on the development of genomics technologies before returning to protein/antibody engineering and biotherapeutics development at Xencor, Inc. Dr. Zhukovsky performed a postdoctoral fellowship at Genentech, Inc. He received a PhD in biochemistry from Brandeis University and an MS degree in bioorganic chemistry at St. Petersburg's State University.